



Griffin House, 53 Regent Place, Birmingham, B1 3NJ

Tel: +44 (0)121 236 1988

Website: www.bsac.org.uk

Charity No: 1093118 VAT No: 442 5855 40

Registered as a company limited by guarantee

in England & Wales No. 4443910

*Registered address: Griffin House, 53 Regent Place,
Birmingham, B1 3NJ*

ANNUAL GENERAL MEETING 2023

The next **Annual General Meeting** of the
British Society for Antimicrobial Chemotherapy
will be held at 13:20hrs on **Thursday 9 May 2024**

CONTENTS

	<i>page</i>
Agenda	2
Unconfirmed minutes of the Annual General Meeting 2022	3-5
Statement of Trustee's responsibility	6
Trustees Report	7-14
Independent Auditor's report	15-16
Financial Statements	17-32
List of new members	33-40
Memorandum of Association	41-42
Articles of Association	43-51

Open to all Members of the BSAC

*Voting rights limited to Ordinary and Honorary Members of
the Society*

AGENDA

1 Apologies for absence

2 To receive the minutes of the 2022 Annual General Meeting

3 President's report

4 Honorary Treasurer's report

To approve:

A The audited accounts for the period 1 October 2021 – 30 September 2022

B The appointment of MacIntyre Hudson as accountants and auditors for the period 1 October 2021-30 September 2022

5 Elections to Membership

To note in accordance with Article 7, the names of 964 individuals elected to Ordinary Membership of the Society for the period October 2020 – September 2021

6 Elections to Council

To note in accordance with:

A Articles 54 – 63, the elections and re-elections of the following officers to the Society:

- Andrew Seaton, Consultant in Infectious diseases and General Medicine and Lead doctor Antimicrobial Management team, NHS Greater Glasgow & Clyde as Vice President-elect (2023-2024), President (2024-2027), Vice President-past President (2027-2029)
- Matthew Dryden, Consultant in Microbiology & Infection, Rare and Imported Pathogens Dept, Porton Down; UK Overseas Territories Program, UKHSA, Nobel House, Westminster, Visiting Chair, St George's University, Grenada, to serve as International Officer (2023-2026)

B Articles 47 – 53, the election of 3 Ordinary Members of Council to serve 2023-2026:

- Ioannis Baltas, Internal Medicine Trainee Year 2, Imperial College Healthcare NHS Trust
- Thomas Ashfield, GP and Senior Medical Adviser, Pfizer, Winchester
- Aoife Fleming, Lecturer in Clinical Pharmacy, Vice Dean of Interprofessional Learning, School of Pharmacy, University Cork Hospital, Cork
- re-election of Naomi Fleming and Ian Gould to serve a 2nd and final term of office.

7 To receive the Trustees report (including reports on meetings, education, journals & grants)

8 Date, time, and place of the next meeting:

Thursday 9 May 2024, QEII Conference Centre, Westminster, London

9 Any other business

Unconfirmed minutes of the meeting of the Annual General Meeting held 10 May 2022

1 Welcome and apologies for absence

The President welcomed Members to the Annual General Meeting, on this the 50th Anniversary of the founding of the Society. being held virtually due to the COVID-19 pandemic. 47 eligible members were in attendance. Apologies for absence were noted.

2 Minutes of the 2021 Annual General Meeting

The minutes of the 2021 Annual General Meeting were **RECEIVED** and **APPROVED** as a true record.

3 President's report

The President reported that he was delighted to report back to the assembly following his first, and very busy, year in office. From which had been a time of consolidation and growth as the Society emerged from the pandemic.

The Assembly noted that the full activities of BSAC are represented in the Trustees report, noting the following highlights of the past year as presented by the President.

The Society once again continued to grow as an influential learned society, supporting and advocating the responsible and effective use of antimicrobial agents across all health economies.

During the past year BSAC continued to develop its portfolio of online open access e-learning courses, with there now being over 50 such courses, including translations into 5 different languages. These included 5 Infection Clinical Dilemma courses, 10 Paediatric Pathway monogram, 5 new e-learning courses and in addition a number of hybrid and fully virtual conferences. It is testament to the quality of the courses that BSAC regularly sees 10,000+ unique learners engaged in online learning each week.

The President reported that Society membership continued to grow, with 3500+ members across 76 countries. Council is considering how to engage and harness the academic, clinical and advocacy prowess of its growing membership, both to improve membership experience and improve effective antimicrobial prescribing and patient outcomes across the globe most effectively.

Global collaborations remain central to the way in which the society is seeking to develop and influence effective antimicrobial use. During the year the Society maintained and built relationships in Middle East, Africa, North and South America, Europe, and Australasia. The Society has halted engagements in both Ukraine and Russia for the time being, but very much hope to be back working with colleagues in both countries at the soonest opportunity.

The Assembly noted that BSAC remains active within civil society and has, over the past year continued to contribute to initiatives that increase public understanding of AMR and its consequences. **Stop Superbugs** worked with local projects in Tanzania and India, practical support, advice, and equipment to help them spread the word and educate schoolchildren and the public on AMR. In addition, the APPG on Antibiotics offers a window through which to influence legislation and government responses to AMR. During the year the group met to examine how to determine safe thresholds of antibiotic residues in sewage/agricultural runoff and how the COVID response might aid efforts to contain and control AMR.

The President was delighted to report that BSAC had continued to support development of The Mould that Changed the World Musical. The musical will feature runs at the Edinburgh Fringe and in Glasgow in 2022 HMG that has led to a planned 4 city run commencing October 2022 in Washington, with further runs planned for Atlanta, New York City and beyond, with support from Rockefeller Foundation and CDC amongst others.

As in previous year, BSAC continued to invest in and develop JAC-AMR, our fully open access journal, in addition to increasing the reach and reputation of the Journal of Antimicrobial Chemotherapy (JAC). Learned publishing provides two flagship activities for the society through which charitable objectives are met.

The President informed members that several new initiatives had been developed over the past 12 months, these included:

- Global Antimicrobial Stewardship Partnership Hub: to be launched end-May 2022, this initiative aims to foster collaboration across organisations globally to accelerate the pace of change needed to address AMR.
- Global Antimicrobial Stewardship Accreditation Scheme (GAMSAS) to support healthcare facilities globally to measure and enhance IPC, data collection / usage and antimicrobial stewardship programmes.
- The Infection Clinical Dilemmas series has proved exceptionally popular with members and colleagues globally – to date we have hosted / planned a suite of 12 webinars, on demand events and e-learning courses – bridging the gap between policy and practice through case based learning.
- The UK Antimicrobial Registry is in development, the registry will collect and report real time data on the use of new agents for multi-drug resistance infections. The registry is run in partnership with the University of Aberdeen, is supported by industry partners and recommended by NICE as a data collection tool for companies within the de-linkage scheme.
- Keep Antimicrobials Working is a UK initiative with international applicability that aims to secure formal training on prescribing within the undergraduate curriculum.

Looking to the future the President reported that the Society is entering a period of programmes' roll out and consolidation, bringing to success the projects outlined in his presentation. He reassured the Assembly that Trustees will continue to safeguard and manage the growth of the society in the new post pandemic world and will additionally continue to be ambitious and unapologetically aspirational as it rises to meet the challenge of antimicrobial resistance.

The President closed by thanking Trustees, Editors, Members, partner organisations and colleagues in industry and philanthropy for their unstinting support of and contributions to BSAC. The support of all stakeholders is especially important as BSAC navigated the challenges the pandemic placed on its operations and finances.

4 Honorary Treasurer's report

The Honorary Treasurer presented the audited accounts for the period 1 October 2020 – 30 September 2021, reminding the assembly that the financial statements comply with the Charities Act 2011, the Companies Act 2006, the Memorandum and Articles of Association, and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015).

The Assembly heard that the accounts under consideration represented a full financial year during which all business was conducted within the pandemic and under lockdown conditions for the vast majority of time. As in the previous year Council continued to build on the risk management and business development strategies adopted at the outset of the pandemic to ensure the Society remained financially healthy and viable. As a result of this, and an increased focus on programmes of work as outlined by the President, the Treasurer was delighted to report that the accounts show an income of expenditure of £468,000. In addition, those present noted a 12.8% (£1.27 million) increase in the total worth of the Society.

It was noted that the charitable spend of the society was 59%, with a 1% spend on governance (greatly reduced due to remote working) and other costs of 40% that includes salaries, suppliers, and estate costs.

Those present joined the Honorary Treasurer in thanking stakeholders across membership, partner organisations, industry and commerce and philanthropy for their support and commitment to the Society over the past year.

The Assembly **APPROVED**:

- A The audited accounts for the period 1 October 2020 – 30 September 2021
- B The appointment of MacIntyre Hudson as accountants and auditors for the period 1 October 2022-30 September 2022.

5 Elections

The Assembly **NOTED** in accordance with Article 7, the names of 964 individuals elected to Ordinary Membership of the Society for the period October 2021 – September 2022.

6 Elections to Council

The Assembly **NOTED** in accordance with:

- A Articles 54 – 63, the elections and re-elections of the following officers to the Society:
- Election of Oliver van Hecke to serve as Grants Secretary 2022–2025
 - Election of Sally Tipping to serve as Education/Meetings Secretary 2022–2025
 - Re-election of Chris Longshaw as Honorary Treasurer to serve 2022–2025
- B Articles 47 – 53, the election of 3 Ordinary Members of Council to serve 2022–2025:
- Louise Sweeney, Consultant Medical Microbiologist, Manchester University NHS Foundation Trust
 - Amelia (Annie) Joseph, Consultant Medical Microbiologist, Nottingham University Hospitals Trust
 - Aimee Murray, Lecturer, European Centre for Environment and Human Health, Environment & Sustainability Institute, University of Exeter
 - Re-election of Mike Allen, MSD for second and final term of office

7 Changes to the Articles of Association

The Assembly **CONSIDERED** and **APPROVED** a number of changes to the Articles of Association, as marked at pages 54–56 of the agenda. The changes were proposed for the following reasons:

- A To make the Articles gender appropriate, currently case in the masculine 'we', now cast as they, their, chairperson etc.
- B To take account of changes to membership subscriptions now that membership is free of charge.
- C To ensure the interests of all members are represented by the appointment from 2023 of an Officer for international affairs.
- D To limit the number of Trustees from outside the UK to 5 (or one third of the membership of the Council).

8 Trustees report

The Assembly **RECEIVED** the Trustees report for the period, including reports on meetings, education, peer review journals and accounts. Date, time, and place of the next meeting: to be notified

9 Next meeting

Thursday 18 May 2023, QEII Conference Centre, London

10 Any other business

There being no other business the meeting was declared closed.

Reference and administrative details of the company, its trustees and advisers for the year ended 30 September 2022

Trustees

Dr Mark Gilchrist
Professor Paul Long
Dr Sanjay Patel
Dr Helena Parsons
Dr Jonathan Sandoe
Dr Philip Howard
Dr Michael Allen
Dr Christopher Longshaw
Enas Newire (resigned 10 June 2022)
Dr Oliver Van Hecke
Dr Naomi Fleming
Daniel Hassan
Dr Jessica Blair (resigned 20 November 2022)
Professor Ian Gould
Sally Tipping
Neil Powell
Dr David Jenkins
Dr Louise Sweeney (appointed 13 June 2022)
Dr Amelia Jones (appointed 13 June 2022)
Dr Aimee Murray (appointed 13 June 2022)

Trustees' Report for the period ended 30 SEPTEMBER 2021

Report of the trustees for the year ended 30 September 2022

The trustees are pleased to present their annual directors' report together with the audited financial statements of the company for the year ending 30 September 2022.

The financial statements have been prepared in accordance with the accounting policies set out in note 1 to the financial statements and comply with the Charity's Memorandum and Articles of Association, the Companies Act 2006, and the Charities SORP (FRS 102) - "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective from 1 January 2019). Reference and administrative details The British Society for Antimicrobial Chemotherapy is both a company limited by guarantee (Registered Company 4443910) and a registered charity (Registered Charity 1093118). It was incorporated on 21 May 2002, having operated as an unincorporated charity since being founded in 1971. The principal and registered address of the Charity is Griffin House, 53 Regent Place, Birmingham, B1 3NJ.

The names of the trustees at the date of approval of the report, and the names of those who served during the financial year are:

1 October 2021 – 30 September 2022

Michael Allen, Medical Affairs, Merck Inc
 Jessica Blair, Academic Microbiologist, Birmingham
 Naomi Fleming, Community based Pharmacist, Towcester
 Mark Gilchrist, Consultant Pharmacist, London
 Ian Gould, Consultant Microbiologist, Aberdeen
 Daniel Hassan, PhD Student, USA
 Oliver Van Hecke, Academic General Practitioner, London
 Philip Howard OBE, Consultant Pharmacist, Leeds
 David Jenkins, Consultant Microbiologist, Leicester
 Helena Parsons, Consultant Microbiologist, Sheffield
 Sanjay Patel, Consultant Infectious Diseases Pediatrician, Southampton
 Neil Powell, Consultant Antimicrobial Pharmacist, Cornwall
 Jonathan Sandoe, Associate Clinical Professor Microbiology, Leeds
 Sally Tipping, Lead Antimicrobial Pharmacist, Swindon
 Christopher Longshaw, Scientific Advisor, Birmingham
 Paul Long, Reader in Pharmacology, London

1 October 2021 – 10 May 2022

Enas Newire, PhD Student, London

10 May 2022 – 30 September 2022

Louise Sweeney, Consultant Medical Microbiologist, Manchester
 Amelia (Annie) Jones, Consultant Medical Microbiologist, Nottingham
 Aimee Murray, Lecturer, Exeter

The name of the Society's Chief Executive Officer, the senior staff member to whom the trustees delegate day-to-day management of Society affairs, is Mrs Tracey Guise.

The names and addresses of the Society bankers, accountants, investment advisers and solicitors are recorded below:

Bankers

Lloyds-TSB
 Colmore Row
 Birmingham, B3 3BP

Accountants

MHA MacIntyre Hudson
 Peterbridge House, The Lakes
 Northampton, NN4 7HB

Investment advisers

Rathbones Management Investment Ltd
159 New Bond Street
London, W1S 2UD

Solicitors

Hempsons Solicitors
20 Embankment Place
London, WC2N 6NN

STRUCTURE, GOVERNANCE AND MANAGEMENT**Governing document**

The governing document is the Memorandum and Articles of Association (MAA) that is regularly reviewed by Council. The Society Regulations further define the MAA. These documents are published on the Society website.

Election of Trustees

Elected Members of Council act as Trustees and Directors of the Society. The procedure for the election of Trustees is set down in the Articles of Association and further defined by the Regulations. In summary, Council comprises Ordinary Members of Council who are elected by an open process of nomination and, when nominations exceed the number of vacancies, by postal ballot of the Membership; this ballot is conducted by the Electoral Reform Services and Officers of the Society who are elected by Council.

Induction of Trustees

An internal induction programme for Trustees exists. Trustees receive an induction pack that includes information on the statutory responsibilities of trustees and directors, structure of the Society and timecommitment/duties of a Trustee. At the time of appointment Trustees are required to confirm their eligibility to serve as a Trustee and complete a declaration of interests form for inclusion on the Society Declaration of Interests Register. In addition, the Society offers the opportunity for all newly appointed and existing Trustees to attend training courses on the roles and responsibilities of Trustees. The cost of these courses is met by the Society.

Pay policy for staff

The pay of the senior staff and all other staff is reviewed annually by Remuneration Committee that comprises senior officers of the society and normally increased in accordance with average earnings. In view of the nature of the charity, the directors benchmark against levels of remuneration in other not for profit organisations and learned societies. The remuneration benchmark is the mid-point of the range paid for similar roles with a single salary scale allowing for salary adjustments for any additional responsibilities. During the past year, the Remuneration Committee received, considered, and made their decisions regarding salary supported by the results of a salary survey information published by HR Expert and the Professional Associations Research Network.

ORGANISATIONAL STRUCTURE AND DECISION MAKING

The Council meets three times annually to consider statutory and financial business and to determine policy for the charity.

Advisory Boards are overseen by elected Officers and/or Trustees and are each responsible for a major area of BSAC activity. Each of the Advisory Boards has delegated authority to carry out work agreed by Council and each report its activities back to Council. Details of the overarching structure, composition and remit of each Committee are published on the Society website.

RISK MANAGEMENT

The Trustees acknowledge their responsibility to assess and manage the risks that the Society faces or might face in future. A consolidated risk register, developed using Charity Commission guidance, is maintained by the Society. Officers and senior staff are required to identify and analyse risks relevant to their responsibilities, assess risks according to their likely occurrence and impact and report on procedures that are in place to manage the risks. The risk management process is overseen and reviewed by Council.

To minimise conflicts of interest, the Society maintains a Register of Interests. Those appointed to act on behalf of the Society (Trustees, Chairs of working parties, editors, referees, etc.) are required to complete a declaration of interests' form, which is recorded centrally at BSAC HQ. Details about the risk register are published on the Society website. There was a full review and update of the risk register and transparency declarations in 2014

and both registers are updated on an annual and ongoing / as required basis. A full review of both registers was undertaken during 2021 and 2022.

REVIEW OF OBJECTIVES, ACTIVITIES, ACHIEVEMENTS AND PERFORMANCE

Objectives

The purpose of the BSAC, as described by the objects of the Society is to “facilitate the acquisition and dissemination of knowledge in the field of antimicrobial chemotherapy.”

Between October and January of each year Council agrees a programme of work for the forthcoming year. This programme of work includes a range of educational, meetings, grant giving and other activities that are in accordance with, and aimed at furthering, the objects of the Society.

During the year Council referenced, adjusted, and worked towards fulfilment of its agreed strategic framework. The strategic framework includes mission statements, key messages, and desired deliverables relevant to the current agreed objectives of the society. The aim of the strategic framework and timetable is to enable all elected officers and Council Members the opportunity to be actively involved in setting the agenda for the future, without having undue influence over it, and regularly measuring progress and outcomes against it. The impact of the COVID19 pandemic continued to influence delivery of activities, with an increasing number of meetings and events held online or in person with the option of online. Naturally the range of online activities increased, namely education and e-learning courses and online conference and workshops offers. The Society continued to evaluate the range of risks and external influences the society was exposed to, including likely changes to the academic publishing market.

Public benefit

The Trustees have read the guidance on public benefit provided by the Charity Commission. The Society ensures that its activities are as far as possible to the public benefit by ensuring patient/public involvement and the development of educational initiatives directly aimed at members of the public. During the past year Dr Nicholas Brown served as the BSAC Director for Professional and Public Engagement, serving as a co-opted member of Council and overseeing the work of the All-Party Parliamentary Group on Antibiotics and the advocacy work it undertakes to raise the profile of antimicrobial resistance within civil society.

Grants

Trustees and the Grants Committee go to great lengths to obtain due diligence in the refereeing of grant applications and continues to support its policy of only supporting those applications that are of a high standard. To ensure that the grant award process is as transparent as possible, the Society has developed Standard Operational Procedures for Grants that are regularly reviewed and updated.

During the year the Society expended funds received from the previous year \$1 million donation for grants that looked at the impact of COVID19 on antimicrobial resistance. The Grants Committee did not meet or make awards during the 2021-22 financial year.

Education

During the year the Society continued to support the development of clear and well-funded initiatives in education that are designed to support the education and training needs of clinicians, junior doctors, scientists, and technicians, in addition to allied health professionals and that are of wider benefit to the public. The Society continued to develop and promote a wide range of courses on antimicrobial resistance, antimicrobial stewardship and the prevention, diagnosis, and treatment of infection. These courses were underwritten by grants from external sources and/or funding from charitable income. All courses are openly and freely available to health care professionals and other interested stakeholders globally, including members of civil society and are housed on the Society's Infection Learning Hub (www.infectionlearninghub.com). The courses have attracted over 275,000 active learners from 6 continents and 205 countries and independent territories across the globe.

Conferences and webinars

Throughout the period the society hosted a range of in person, hybrid and online conferences and webinars, the outputs of which are available on demand as recorded events, and for the Infection Clinical Dilemmas series include e-learning courses that extend the value and reach of the learning provided.

Web-based educational resources

During the period the Society maintained the range of educational resources available via its website. These include:

Webcasts and PowerPoint slide sets: This facility increases the number of individuals able to benefit from the Society's educational programmes and provides valuable learning materials for those unable to attend meetings in person.

Education around antimicrobial prescribing remains as one of the key strategies for supporting antimicrobial stewardship activities, and both resources and other e-learning modules aim to educate and empower health care professionals to provide high quality and safe infection prevention and management across healthcare communities that will enhance the health of the populations they serve. The Society maintained an open access repository of peer review and non-peer review resources to support health care professionals across the globe to support the World Health Organisation global action plan on antimicrobial resistance. During the year the Society examined how to translate its rich repository of open access learning into more focused training courses, agreeing to develop a series of Masterclass Training Courses, development of which will commence in October 2022.

Susceptibility Testing

The Society continued to support the United Kingdom contribution to the European Antimicrobial Susceptibility Testing methodology – EUCAST and underwrote a service provision contract in this area with Public Health Wales. This activity fulfils the three-main charitable objective headings as the Society educates health professionals in susceptibility testing methodology, communicates outputs to the Membership and wider profession and undertakes research to ensure the European methodology is accurate and continually updated.

Resistance Surveillance

During the year the Society, finalised transfer of a biobank of over 50,000 clinically significant isolates from the Resistance Surveillance programme to a consortia research group led by Universities of Dundee and Edinburgh. This followed a competitive application process. Whilst this marked the formal end of the surveillance programme after more than two decades, the Society will, under contract, continue to benefit from any commercialisation of research arising from use of the isolates over a period of 5 years and as importantly researchers will still be able to access the isolates for ongoing research for many years to come.

Outpatient Parenteral Antimicrobial Therapy (OPAT)

The Society published on a dedicated website the outputs of its Outpatient Parenteral Antimicrobial Therapy (OPAT) project, which supports establishing treatment services for serious infections in the home environment. The Society continued to support, through meetings and provision of free at point of use resources, the development and implementation of services within the UK. The programme continued to support the Drug Stability initiative during the year to provide open access data on the stability of medicines in elastomeric devices, data currently not openly available to the field. Details of all work in progress can be reviewed at www.eopat.com.

Meetings

The Society hosted and/or participated in many national and international meetings during the year.

All Society organized meetings, e-learning courses and webinars are accredited for Continuing Professional Development under the statutory scheme operated by the Royal College of Pathologists, and when appropriate, the Royal College of Physicians of London. The Society is required, as part of this process, to issue evaluation questionnaires for each event. The responses provided by these anonymous returns allow the Society to monitor the effectiveness of its activities in this area and enables measures for improvement to be introduced.

Major work streams

During the year the Society worked on the development of the following five major workstreams/activities:

The United Kingdom Antimicrobial Registry (UKAR), developed in partnership with the University of Aberdeen, is a prospective study that will secure longitudinal data on the use of new antimicrobial agents across the United Kingdom.

The Global Antimicrobial Stewardship Accreditation Scheme (GAMSAS) is a continuous quality improvement programme that will drive improvements in appropriate use of antimicrobial prescribing at healthcare facilities across the globe.

The Global Antimicrobial Stewardship Partnership hub (GASP-h) is a globally collaborative initiative aimed at fostering meaningful and impactful partnership working across all stakeholder groups engaged the development and use of antimicrobial agents.

Keep Antimicrobials Working (KAW) is an initiative with representation from the Society, medical schools in the UK and the British Pharmacological Society. Whilst initially UK focused the initiative has international applicability and aims to ensure antimicrobial prescribing is formally embedded within the undergraduate curricula.

The Paediatric workstream has published pathways for the management / treatment of infections in paediatric populations and includes peer reviewed good practice recommendations supported by open access e-learning courses.

BSAC International

Despite its "British" title the Society has an international membership, and its peer review journal is internationally recognised and renowned. This is also reflected in the activities undertaken by the Society, many of which influence not only UK practice but also contribute to the shaping of international practice, opinion, and research.

During the period, the Society hosted sessions and/or supported speakers at many international meetings and developed collaborative relationships with several external groups. Full details of collaborative relationships, especially those fostered through GASPH are published on the BSAC website.

Public facing activities

Council continued to fulfil its aim of improving public education about infection prevention and appropriate use of antibiotics through a range of activities, including its global community project focused initiative Stop Superbugs and within the UK through provision of the Secretariat to the All Party Parliamentary Group on Antibiotics.

During the period the Society continue to advocate the use of the e-Bug educational website that contributes to national and Europe-wide curricula for primary school children. The Society worked with the United Kingdom Health Security Agency (UKHSA) to revise the e-Bug teaching materials and relaunch the overarching website. In addition, the Society continues to support onward development of Mould the Musical, both school and professional versions, engaging with Her Majesty's Government offices in the US to secure international runs of the musical in Washington DC, Atlanta, and New York City, works which will continue into 2023 and beyond.

Stop Superbugs continued to provide support to local projects across the globe, with the aim being to offer modest but impactful support to local projects that aim to prevent infection and improve understanding about antimicrobial resistance.

The Society continued to serve as secretariat to the All-Party Parliamentary Group on Antibiotics and the group continues to ensure that the topics of antibiotic discovery, development, and resistance receive the political interest required to ensure current and future action.

Communication

The Society continues to communicate with its membership via many different media, including its journals, email, website, e-newsletters, and scientific meetings. The Society worked on development of a new content management system (CMS) to improve efficiencies in data management and membership/stakeholder engagement.

The Society's websites remain one of the primary routes through which BSAC communicates with the membership and wider community. The sites are open to Members and non-Members alike and provide visitors with easy access to resources on antimicrobial chemotherapy and its allied fields.

BSAC continues to recognise the importance of, and extend its reach via, social media outlets such as Twitter, LinkedIn and Facebook and used viral networking opportunities to deliver messages about appropriate use of antibiotics to public audiences.

Working with others

The Society's relationships with its sister organisations, industry and government are key in ensuring the successful delivery of the Society's agenda. The Society continued to work with many organisations that across the globe, diversifying engagements outside of health and pharmaceutical industry to include investment banks and international organisations such as WaterAid, UNICEF and Medicines Sans Frontiers.

The Society continued to develop its relationships with all health care professional groups engaged in antimicrobial use and prescribing, including those outside of human health such as veterinarians, animal husbandry and environmental science. Through the inclusion of all relevant stakeholders in its activities BSAC continues to ensure that there is a unified voice on infection prevention, detection, and management in the UK, in addition to working on the wider impact of antimicrobial use in other sectors (one health).

The Society is mindful of the need to engage meaningfully with patients to take on board their views and meet their needs and does so through representation in its activities as and when appropriate, and through the establishment of a Patients Charter to support patient charities to support their members in gaining a better understanding of the importance of antibiotics and their appropriate use.

JAC-Antimicrobial Resistance

The Society's fully open access journal launched in 2019 - JAC-Antimicrobial Resistance (JAC-AMR) continued to develop during the year. The education component of JAC-AMR is an innovative online repository for educational resources intended to support learning and increase knowledge about antimicrobial stewardship practice, antimicrobial resistance, behaviour change and more, for a worldwide audience. The research component will publish clinically oriented opinions, reviews and original articles that advance the science and knowledge of antimicrobial resistance, stewardship and use relating to antibacterial, antifungal, antiviral and antiprotozoal agents. The Journal publishes primarily in human medicine, but articles in veterinary medicine will be considered, provided they fall within the scope of a regional or global 'one health' approach to antimicrobials.

Journal of Antimicrobial Chemotherapy

The Journal continues to be recognized as a leader in its field and is one of the major routes by which the Society fulfils its educational objectives to disseminate information about antimicrobial chemotherapy.

The Journal content becomes freely available on-line 12 months after publication, thus benefiting the profession and consumers alike.

Other significant matters

The Society continued to work towards diversification of income streams during this period, to reduce risk of reliance on income from the journal and continued to review its supplier base to ensure best value for money and ensure spread of risk. Most notably a full review of internal editorial services was undertaken. This resulted in a decision to outsource editorial functions wholly to the publisher, Oxford University Press, resulting in the regrettable but necessary redundancies. This action was part of the Society's risk management strategy, which looks at risks both present and projected.

Financial review

The audited accounts for the period 1 October 2021 – 30 September 2022 are included in this report.

The Society remains financially sound and to maintain this position, Trustees continued to review the Society's financial planning and budgeting procedures, as defined in the financial standing orders. The Society is within the infection arena and as such there is a demand for the services it provides which, within a difficult financial

climate for some, provides reassurance for the financial viability of the Society. The Society adheres to the principles for expenditure and expense claim guidance that is published on the BSAC website. In 2021-22 the Society continued to operate an annual budgeting and planning process, which was overseen and approved by Council, and as of this period built according to the new governance structure.

During the period the principal sources of funding were income from the Journal of Antimicrobial Chemotherapy, and revenue from meetings activities in the form of delegate registration fees and unrestricted educational grants/donations from Industry, and philanthropic donations. Income from the external publishers of the Journal of Antimicrobial Chemotherapy was £1,317,460 less external publisher's expenses £237,272 realising net income of £1,080,188 before additional in-house editorial costs.

The Society is very grateful to several pharmaceutical and diagnostic companies that generously provided unrestricted educational grants that enabled the Society to deliver educational benefits through meetings to delegates at greatly reduced, or complimentary, rates.

As planned, Council spent £1,099,604 from the designated funds, the majority of which was expended on the Society's public engagement programme.

The general fund is largely represented by the investment portfolio, which performed well in a difficult market with realised and unrealised losses of £515,638. The Society developed revised contractual arrangements for the supply of isolates to academic and commercial contractors, primarily for use in research projects. The Trustees intend to retain the investment portfolio to generate income that will support the long-term fulfilment of the Society's charitable objectives.

To ensure compliance with the law as established by the Bribery Act 2010, Council has developed and approved an Anti-Bribery Policy Statement, a copy of which is published on the Society website.

Council remains mindful of the need to ensure funds are dispersed in furtherance of its aims through a range of charitable activities. The Society now has designated funds for future allocation of funds to grant, education and meeting activities. Further, the Society has a restricted fund through which it supports the national programme of resistance surveillance.

Council has charged itself with continuing to examine the range of general, designated, and restricted funds it holds to ensure that monies are transferred and dispersed on grants, resistance surveillance, and education and meetings activities in an appropriate and timely fashion.

Investments

The Society investment portfolio is managed by Rathbones Management Investments Ltd, with whom Officers of the Society meet on an annual basis to review and discuss future policy for Society investments. Target income from investments is set at £100,000pa.

The charity's investments are managed according to the powers defined by the Memorandum and Articles of Association. A balanced investment portfolio is maintained, and the investment advisers have been charged with increasing income from investments whilst protecting the capital value of the fund, this being the policy position of Council. The Society has placed certain restrictions on the way in which the fund is managed, including precluding investments in named pharmaceutical companies to ensure conflicts of interest, perceived or real, do not arise.

Reserves

The Trustees' policy is to maintain a level of free reserves equivalent to not less than 24 months expenditure and aim to have a reserve for 36 months expenditure. This policy would enable the Society to remain operational for between 24-36 months (estimated at £4 million against total free reserves of £8,602,045 and fulfil its commitments in terms of research, grants, education, and meetings activities, some of which are subject to a 3-year planning / completion cycle.

The future

Despite a year in which investments performed badly, due to a number of major world events including war and conflicts, the Trustees remain confident that the Society is, through the activities described in this report, financially robust and will continue in meeting and furthering the aims and objectives of the Society. Through

careful planning and collaboration with the Membership and relevant external organisations, Trustees will continue to deliver and develop these activities.

The Trustees have a reasonable expectation that the charity will continue in operational existence for the foreseeable future and have, therefore, used the going concern basis in preparing the financial statements.

TRUSTEES' RESPONSIBILITIES STATEMENT

The Trustees (who are also directors of British Society for Antimicrobial Chemotherapy for the purposes of company law) are responsible for preparing the Trustees' report (incorporating a directors' report) and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial year. Under company law the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Charity and of their incoming resources and application of resources, including their income and expenditure, for that period. In preparing these financial statements, the

Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP (FRS 102);
- make judgments and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards (FRS 102) have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in operation.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the Charity's transactions and disclose with reasonable accuracy at any time the financial position of the Charity and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the the Charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

STATEMENT AS TO DISCLOSURE OF INFORMATION TO AUDITORS

Each of the persons who are Trustees at the time when this Trustees' report is approved has confirmed that:

- so far as that Trustees are aware, there is no relevant audit information of which the charitable company's auditor is unaware, and
- that the Trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information.

INDEPENDENT AUDITORS

MHA MacIntyre Hudson has indicated its willingness to continue in office, and as such is deemed to be reappointed under section 487 (2) of Companies Act 2006.

This report was approved by the Trustees, and signed on their behalf by:

Dr Christopher Longshaw

Trustee

Independent Auditors' report to the members of British Society for Antimicrobial Chemotherapy

OPINION

We have audited the financial statements of British Society for Antimicrobial Chemotherapy (the 'charitable company') for the year ended 30 September 2022 which comprise the Statement of financial activities incorporating income and expenditure account, the Balance sheet, the Statement of cash flows and the related notes, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 30 September 2022 and of its incoming resources and application of resources, including its income and expenditure for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

BASIS FOR OPINION

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the United Kingdom, including the Financial Reporting Council's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

CONCLUSIONS RELATING TO GOING CONCERN

In auditing the financial statements, we have concluded that the Trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report.

OTHER INFORMATION

The Trustees are responsible for the other information. The other information comprises the information included in the Annual report, other than the financial statements and our Auditor's report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

MATTERS ON WHICH WE ARE REQUIRED TO REPORT BY EXCEPTION

We have nothing to report in respect of the following matters where the Charities (Accounts and Reports) Regulations 2008 requires us to report to you if, in our opinion:

- the information given in the Trustees' report is inconsistent in any material respect with the financial statements; or
- sufficient accounting records have not been kept; or
- the financial statements are not in agreement with the accounting records and returns; or
- we have not received all the information and explanations we require for our audit.

RESPONSIBILITIES OF TRUSTEES

As explained more fully in the Trustees' Responsibilities Statement, the Trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

AUDITOR'S RESPONSIBILITIES FOR THE AUDIT OF THE FINANCIAL STATEMENTS

We have been appointed as auditor under the Companies Act 2006 and report in accordance with the Act and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements. Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

- Enquiry of management and those charged with governance around actual and potential litigation and claims;
- Enquiry of entity staff to identify any instances of non-compliance with laws and regulations;
- Performing audit work over the risk of management override of controls, including testing of journal entries and other adjustments for appropriateness and reviewing accounting estimates for bias;
- Reviewing minutes of meetings of those charged with governance;
- Reviewing financial statement disclosures and testing to supporting documentation to assess compliance with applicable laws and regulations.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our Auditor's report.

USE OF OUR REPORT

This report is made solely to the charitable company's Trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. Our audit work has been undertaken so that we might state to the charitable company's Trustees those matters we are required to state to them in an Auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and its Trustees, as a body, for our audit work, for this report, or for the opinions we have formed.

Rebecca Hughes BSc (Hons) FCCA (Senior Statutory Auditor)

for and on behalf of
MHA MacIntyre Hudson
Statutory Auditors
Northampton, United Kingdom

MHA MacIntyre Hudson are eligible to act as auditors of section 1212 of the Companies Act 2006.

Statement of financial activities (incorporating an income and expenditure account) for year ended 30 September 2021

	Note	Unrestricted funds 2022 £	Restricted funds 2022 £	Total funds 2022 £	Total funds As restated 2021 £
INCOME FROM:					
Donations	2	207,567	30,055	237,622	174,720
Charitable activities	3	1,860,431	532,960	2,393,391	2,160,001
Investments	4	150,469	-	150,469	196,088
TOTAL INCOME		2,218,467	563,015	2,781,482	2,530,809
EXPENDITURE ON:					
Raising funds		25,173	-	25,173	12,980
Charitable activities	5/6	2,272,758	406,533	2,679,291	1,978,513
TOTAL EXPENDITURE	7	2,297,931	406,533	2,704,464	1,991,493
NET (EXPENDITURE) / INCOME BEFORE INVESTMENT GAINS					
Net gains/(losses) on investments		(79,464)	156,482	77,018	539,316
		(515,638)	-	(515,638)	794,982
NET (EXPENDITURE) / INCOME BEFORE OTHER RECOGNISED (LOSSES) AND GAINS					
		(595,102)	156,482	(438,620)	1,334,298
Transfers between Funds	16	10,245	(10,245)	-	-
NET INCOME / (EXPENDITURE) BEFORE OTHER RECOGNISED GAINS AND LOSSES					
		(584,857)	146,237	(438,620)	1,334,298
NET MOVEMENT IN FUNDS					
		(584,857)	146,237	(438,620)	1,334,298
RECONCILIATION OF FUNDS:					
Total funds brought forward		9,186,902	1,101,121	10,288,023	8,953,725
TOTAL FUNDS CARRIED FORWARD		8,602,045	1,247,358	9,849,403	10,288,023

The notes on pages 20 to 32 form part of these financial statements.

Balance sheet as at 30 September 2021

	Note	£	2022 £	£	2021 As restated £
FIXED ASSETS					
Tangible assets	11	1,039,202		1,078,392	
Investment property	12	550,000		550,000	
Total tangible assets			1,589,202		1,628,392
Investments	13		5,704,606		6,297,104
			7,293,808		7,925,496
CURRENT ASSETS					
Debtors	14	740,544		377,992	
Cash at bank and in hand		2,366,890		2,346,752	
		3,107,434		2,724,744	
CREDITORS: amounts falling due within one year	15	(551,839)		(362,217)	
NET CURRENT ASSETS			2,555,595		2,362,527
NET ASSETS			9,849,403		10,288,023
CHARITY FUNDS					
Restricted funds	16	1,247,358		1,101,121	
Unrestricted funds	16	8,602,045		9,186,902	
TOTAL FUNDS			9,849,403		10,288,023

The company's financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The Trustees consider that the company is entitled to exemption from the requirement to have an audit under the provisions of section 477 of the Companies Act 2006 ("the Act") and members have not required the company to obtain an audit for the year in question in accordance with section 476 of the Act. However, an audit is required in accordance with section 144 of the Charities Act 2011.

The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.

The financial statements were approved and authorised for issue by the Trustees and signed on their behalf, by:

Dr Christopher Longshaw
Trustee

The notes on pages 20 to 32 form part of these financial statements.

Statement of cash flows for the year ended 30 September 2021

	Note	2022 £	2021 £
Cash flows from operating activities			
Net cash (used in)/provided by operating activities	18	<u>(170,883)</u>	<u>599,400</u>
Cash flows from investing activities:			
Dividends, interest and rents from investments		112,821	161,172
Purchase of tangible fixed assets		-	(374,105)
Proceeds from sale of investments		387,965	674,245
Purchase of investments		<u>(309,765)</u>	<u>(933,478)</u>
Net cash provided by/(used in) investing activities		<u>191,021</u>	<u>(472,166)</u>
Change in cash and cash equivalents in the year		20,138	127,234
Cash and cash equivalents brought forward		<u>2,346,752</u>	<u>2,219,518</u>
Cash and cash equivalents carried forward	19	<u><u>2,366,890</u></u>	<u><u>2,346,752</u></u>

The notes on pages 20 to 32 form part of these financial statements.

Notes to the financial statements for the year ended 30 September 2021

1. ACCOUNTING POLICIES

1.1 General information

The British Society for Antimicrobial Chemotherapy is a private limited company limited by guarantee and registered in England and Wales. Registered company number 04443910 and charity number 1093118. The registered office and principal trading address is Griffin House, 53 Regent Place, Birmingham, B1 3NJ.

1.2 Basis of preparation of financial statements

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) – Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

British Society for Antimicrobial Chemotherapy meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

1.3 Company status

The company is a company limited by guarantee. The members of the company are the Trustees named on page 1. In the event of the company being wound up, the liability in respect of the guarantee is limited to £1 per member of the company.

1.4 Going concern

The financial statements have been prepared on a going concern basis. The Trustees have considered relevant information, including the post year end performance and the impact of subsequent events in making their assessment. Based on these assessments and having regard to the resources available to the entity, the Trustees have concluded that there is no material uncertainty and that they can continue to adopt the going concern basis in preparing the annual report and accounts.

1.5 Income

All income is recognised once the company has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

Donated services

No value has been attributed, as amounts involved, where an objective value can be determined, are not material.

Research grant funding

Income receivable to support research studies is recognised at fair value when the charity has entitlement after any performance conditions have been met, it is probable that the income will be received and the income can be measured reliably. If entitlement is not met, relevant amounts are deferred.

Foreign currencies

Monetary assets and liabilities denominated in foreign currencies are translated at the rate of exchange ruling at the Balance Sheet date. Transactions in foreign currencies are recorded at the rate ruling at the date of the transaction. All differences are taken to the Statement of Financial Activities.

Quoted investments and investment property

Quoted investments are stated at market value at the year end. Gains and losses on disposal and revaluation of investments are charged or credited to the SOFA.

Investment properties are revalued annually, therefore no depreciation is provided in respect of investment properties. The Trustees consider that, because these properties are not held for consumption but for their investment potential, to depreciate them would not give a true and fair view.

1.6 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the

amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use.

Governance costs are those incurred in connection with administration of the company and compliance with constitutional and statutory requirements.

Costs of generating funds are costs incurred in attracting voluntary income, and those incurred in trading activities that raise funds.

Charitable activities and Governance costs are costs incurred on the company's operations, including support costs and costs relating to the governance of the company apportioned to charitable activities.

Grants payable are charged in the year when the offer is made except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attaching are fulfilled. Grants offered subject to conditions which have not been met at the year end are noted as a commitment, but not accrued as expenditure.

1.7 Tangible fixed assets and depreciation

All assets costing more than £1,000 are capitalised.

Tangible fixed assets are carried at cost, net of depreciation and any provision for impairment.

Depreciation is provided at rates calculated to write off the cost of fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Freehold property (exc. land) - 2% straight line

Property improvements - 20 years straight line

Computer and other equipment - 25% straight line

1.8 Investments

Fixed asset investments are a form of financial instrument and are initially recognised at their transaction cost and subsequently measured at fair value at the Balance sheet date, unless fair value cannot be measured reliably in which case it is measured at cost less impairment. Investment gains and losses, whether realised or unrealised, are combined and shown in the heading 'Gains/(losses) on investments' in the Statement of financial activities incorporating income and expenditure account.

1.9 Interest receivable

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the company; this is normally upon notification of the interest paid or payable by the Bank.

1.10 Debtors

Trade and other debtors are recognised at the settlement amount after any trade discount offered.

Prepayments are valued at the amount prepaid net of any trade discounts due.

1.11 Cash at Bank and in hand

Cash at bank and in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

1.12 Liabilities and provisions

Liabilities are recognised when there is an obligation at the Balance sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably. Liabilities are recognised at the amount that the company anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide. Provisions are measured at the best estimate of the amounts required to settle the obligation. Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised within interest payable and similar charges.

1.13 Financial instruments

The company only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

1.14 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the company and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the company for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

1.15 Critical accounting estimates and areas of judgment

Estimates and judgments are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Sources of estimation uncertainty:

Depreciation on tangible assets

Investment property valuations are based on property market data at the year end.

2. INCOME FROM DONATIONS

	Unrestricted funds 2022 £	Restricted funds 2022 £	Total funds 2022 £	Total funds As restated 2021 £
Voluntary income: subscriptions	5,500	-	5,500	11,020
Sundry income	50,172	-	50,172	19,290
Antibiotic Guardian	-	2,029	2,029	-
Grant income	151,895	28,026	179,921	144,410
	<u>207,567</u>	<u>30,055</u>	<u>237,622</u>	<u>174,720</u>
Total 2021	<u>30,310</u>	<u>144,410</u>	<u>174,720</u>	

3. INCOME FROM CHARITABLE ACTIVITIES

	Unrestricted funds 2022 £	Restricted funds 2022 £	Total funds 2022 £	Total funds As restated 2021 £
Education	542,971	27,960	570,931	730,918
Communications	1,317,460	-	1,317,460	1,355,393
Research	-	505,000	505,000	73,690
	<u>1,860,431</u>	<u>532,960</u>	<u>2,393,391</u>	<u>2,160,001</u>
Total 2021	<u>2,115,001</u>	<u>45,000</u>	<u>2,160,001</u>	

EDUCATION

	2022 £	2021 £
MOOC-AS including translations	-	9,000
OPAT	56,023	13,000
Spring Meeting	84,444	68,899
Winter Meeting	151,199	100,578
Stop Superbugs	-	3,145
Other meetings/workshops	81,418	233,103
E Learning	169,887	303,193
BCP Project funding	27,960	-
	<u>570,931</u>	<u>730,918</u>
Total	<u><u>570,931</u></u>	<u><u>730,918</u></u>

COMMUNICATION

	2022 £	2021 £
Income arising from the society journal and supplements	1,317,460	1,336,266
Resistance surveillance income (40% of total)	-	19,127
	<u>1,317,460</u>	<u>1,355,393</u>
Total	<u><u>1,317,460</u></u>	<u><u>1,355,393</u></u>

RESEARCH

	2022 £	2021 £
Resistance surveillance income (60% of total)	-	28,690
UKAR	505,000	45,000
	<u>505,000</u>	<u>73,690</u>
Total	<u><u>505,000</u></u>	<u><u>73,690</u></u>

4. INVESTMENT INCOME

	Unrestricted funds 2022 £	Restricted funds 2022 £	Total funds 2022 £	Total funds As restated 2021 £
Rental income	36,468	-	36,468	35,845
Listed investments	112,821	-	112,821	161,172
Bank interest and other investments	1,180	-	1,180	(929)
	<u>150,469</u>	<u>-</u>	<u>150,469</u>	<u>196,088</u>
Total 2021	<u><u>196,088</u></u>	<u><u>-</u></u>	<u><u>196,088</u></u>	

5. DIRECT COSTS

	Education £	Communica tions £	Research £	Total 2022 £	Total 2021 As restated £
Meetings	497,658	-	-	497,658	170,928
Sensitivity testing	-	-	31,189	31,189	10,065
Resistance surveillance	-	-	37,520	37,520	18,109
Journal - editorial fees	92,099	55,540	-	147,639	172,533
Journal - direct publishing	306,641	-	-	306,641	389,517
Research grants	-	-	237,964	237,964	129,205
Stewardship surveillance	28,700	-	-	28,700	-
UKAR	78,770	-	-	78,770	-
Staff training	-	-	-	-	1,574
Miscellaneous	575	-	-	575	913
Other indirect costs	75,121	37,259	74,968	187,348	346,151
Wages and salaries	203,333	203,334	203,334	610,001	474,572
National insurance	20,030	20,030	20,030	60,090	53,177
Pension costs	66,145	66,145	66,145	198,435	166,500
E Learning	171,921	-	-	171,921	47,309
NORS	-	-	-	-	1,491
Drug stability	40,578	-	-	40,578	9,452
Event refund	(20,277)	-	-	(20,277)	(47,753)
	<u>1,561,294</u>	<u>382,308</u>	<u>671,150</u>	<u>2,614,752</u>	<u>1,943,743</u>
Total 2021	<u>509,660</u>	<u>918,569</u>	<u>515,514</u>	<u>1,943,743</u>	

Other indirect allocated costs

Other indirect allocated costs principally comprise of professional fees, computer costs, premises and accommodation costs of the Society's Headquarters.

Wages, national insurance and pension costs

It has been decided, following an increase in core staff, that staffing costs will from 2017-18 onwards be split equally across the three charitable objective headings of research, communication and education.

EDUCATION - MEETINGS

	2022	2021
	£	£
Spring meeting	76,079	44,913
Winter meeting	54,430	28,000
ARM	23,822	15,500
Mould the Musical underwrite	160,000	-
ECCMID	9,631	35,010
Paediatric Conference	6,646	-
OPAT conference	34,208	42,291
International AMS Projects	32,000	-
Antimicrobial Chemotherapy Conference	2,000	4,590
Gram Negative Conference	18,908	-
Infection Clinical Dilemmas	32,800	300
Pneumonia	9,800	-
Webinars	35,834	-
Russia Round Table	1,500	324
	<hr/>	<hr/>
Total	497,658	170,928
	<hr/> <hr/>	<hr/> <hr/>

RESEARCH GRANTS

	2022	2021
	£	£
Covid-19	237,964	129,205
	<hr/> <hr/>	<hr/> <hr/>

5. GOVERNANCE COSTS

	Unrestricted funds 2022 £	Restricted funds 2022 £	Total funds 2022 £	Total funds 2021 £
Auditor's remuneration	8,435	-	8,435	8,435
Auditor's non audit costs	25,317	-	25,317	25,953
Travel	30,787	-	30,787	382
	<hr/>	<hr/>	<hr/>	<hr/>
	64,539	-	64,539	34,770
	<hr/> <hr/>	<hr/> <hr/>	<hr/> <hr/>	<hr/> <hr/>

7. ANALYSIS OF EXPENDITURE BY EXPENDITURE TYPE

	Other costs 2022 £	Total 2022 £	Total 2021 £
Expenditure on investment management	25,173	25,173	12,980
Costs of raising funds	25,173	25,173	12,980
Education	1,561,294	1,561,294	516,819
Communications	382,308	382,308	916,187
Research	671,150	671,150	510,737
Charitable activities	2,614,752	2,614,752	1,943,743
Expenditure on governance	64,539	64,539	34,770
	2,704,464	2,704,464	1,991,493
Total 2021	1,991,493	1,991,493	

8. NET INCOME/(EXPENDITURE)

This is stated after charging:

	2022 £	2021 £
Depreciation of tangible fixed assets: - owned by the charity	39,190	33,230
Auditor's remuneration - audit	8,435	8,435
Auditor's remuneration - other services	25,317	25,953

During the year, no Trustees received any remuneration (2021 - £NIL).
During the year, no Trustees received any benefits in kind (2021 - £NIL).

9. STAFF COSTS

During the year 5 members of staff received redundancy settlements totalling £126,494, as follows:

	£
Pension	29,901
Redundancy	96,593

The average number of persons employed by the charitable company during the year was as follows:

	2022 No.	2021 No.
Employees	13	12

The number of higher paid employees was:

	2022	2021
	No.	No.
In the band £60,001 - £70,000	1	2
In the band £80,001 - £90,000	1	0
In the band £90,001 - £100,000	1	0
In the band £100,001 - £110,000	1	0

One of the above employees is considered to be a key management personnel. The total amount of employee benefits (including employer pension contributions) received by key management personnel for their services to the the charity was £106,910 (2021 - £103,128).

Total staff costs for the year amounted to £868,526 (2021 - £694,249) including Employers National Insurance of £60,090 (2021 - £53,177) and Employers pension contributions of £198,435 (2021 - £166,500).

10. GRANT COMMITMENTS

At 30 September 2022 the total of the Charity's future grants payable were as follows:

	2022	2021
	£	£
Grant commitments	432,828	670,792

11. TANGIBLE FIXED ASSETS

	Freehold property £	Computer and other equipment £	Total £
Cost			
At 1 October 2021 and 30 September 2022	1,295,954	193,328	1,489,282
Depreciation			
At 1 October 2021	219,099	191,791	410,890
Charge for the year	38,692	498	39,190
At 30 September 2022	257,791	192,289	450,080
Net book value			
At 30 September 2022	1,038,163	1,039	1,039,202
At 30 September 2021	1,076,855	1,537	1,078,392

12. INVESTMENT PROPERTY

	Long term leasehold investment property £
Valuation	
At 1 October 2021 and 30 September 2022	550,000

The valuation reflects market movements and takes into account expected rental yields since the last valuation performed in 2017 by Mr M Cook of KWB Property Management Limited, who is a chartered surveyor and an RCIS Registered Valuer. The trustees consider this to be an accurate reflection of the property value as at the balance sheet date.

During the year ended 30 September 2021, the society agreed to grant a purchase option on the property to a third party developer for a value of £830,838 (exclusive of VAT).

13. FIXED ASSET INVESTMENTS

	Listed securities £
Market value	
At 1 October 2021	6,297,104
Additions	309,765
Disposals	(387,965)
Revaluations	(514,298)
	<hr/>
At 30 September 2022	5,704,606 <hr/> <hr/>

Quoted investments

	Cost £	2022 Market value £	Cost £	2021 Market value £
Fixed interest securities UK	1,116,935	1,043,804	967,136	986,834
Equities UK	1,278,764	1,636,686	1,393,346	2,117,008
Equities overseas	1,500,835	2,305,350	1,508,134	2,534,753
Alternatives	552,675	718,764	552,989	658,507
	<hr/>	<hr/>	<hr/>	<hr/>
Total	4,449,209 <hr/> <hr/>	5,704,604 <hr/> <hr/>	4,421,605	6,297,102 <hr/> <hr/>

14. DEBTORS

	2022 £	2021 £
Trade debtors	674,527	312,111
Other debtors	-	47,259
Prepayments and accrued income	66,017	18,622
	<hr/>	<hr/>
	740,544 <hr/> <hr/>	377,992 <hr/> <hr/>

15. CREDITORS: Amounts falling due within one year

	2022 £	2021 As restated £
Other taxation and social security	48,392	90,382
Other creditors	54,658	16,294
Accruals and deferred income	448,789	255,541
	<u>551,839</u>	<u>362,217</u>

	£
Deferred income	
Deferred income at 1 October 2021	109,103
Resources deferred during the year	333,883
Amounts released from previous years	(109,103)
	<u>333,883</u>
Deferred income at 30 September 2022	<u>333,883</u>

Deferred income comprises rental income and project income received in advance.

16. STATEMENT OF FUNDS**STATEMENT OF FUNDS - CURRENT YEAR**

	Balance at 1 October 2021 As restated £	Income £	Expenditure £	Transfers in/out £	Gains/ (Losses) £	Balance at 30 September 2022 £
Unrestricted funds						
General Funds - all funds	<u>9,186,902</u>	<u>2,218,467</u>	<u>(2,297,931)</u>	<u>10,245</u>	<u>(515,638)</u>	<u>8,602,045</u>
Restricted funds						
Resistance surveillance	49,459	-	(37,521)	-	-	11,938
Donations re. Covid-19	670,792	-	(237,964)	-	-	432,828
Spanish translation of the EWMA Wound Management Course	10,245	-	-	(10,245)	-	-
Sponsor of Webinar	97,493	27,960	-	-	-	125,453
Educational grant University of Aberdeen (UKAR)	76,000	3,026	-	-	-	79,026
Drug stability	45,000	505,000	(78,770)	-	-	471,230
Ebug Website	152,132	-	(40,578)	-	-	111,554
Antibiotic Guardian	-	25,000	(10,500)	-	-	14,500
	-	2,029	(1,200)	-	-	829
	<u>1,101,121</u>	<u>563,015</u>	<u>(406,533)</u>	<u>(10,245)</u>	<u>-</u>	<u>1,247,358</u>
Total of funds	<u>10,288,023</u>	<u>2,781,482</u>	<u>(2,704,464)</u>	<u>-</u>	<u>(515,638)</u>	<u>9,849,403</u>

STATEMENT OF FUNDS – PRIOR YEAR

	Balance at 1 October 2020 As restated £	Income £	Expenditure £	Transfers in/out £	Gains/ (Losses) £	Balance at 30 September 2021 £
General Funds - all funds	7,644,847	2,433,809	(1,807,916)	121,180	794,982	9,186,902
Restricted funds						
Resistance surveillance	67,568	-	(18,109)	-	-	49,459
Drive AB	209,673	-	-	(209,673)	-	-
Donations re. Covid-19	799,997	-	(129,205)	-	-	670,792
Spanish translation of the EWMA Wound Management Course	10,245	-	-	-	-	10,245
Sponsor of Webinar	9,000	-	-	88,493	-	97,493
Educational grant	24,000	52,000	-	-	-	76,000
University of Aberdeen	-	45,000	-	-	-	45,000
Drug stability	188,395	-	(36,263)	-	-	152,132
	<u>1,308,878</u>	<u>97,000</u>	<u>(183,577)</u>	<u>(121,180)</u>	<u>-</u>	<u>1,101,121</u>

SUMMARY OF FUNDS – CURRENT YEAR

	Balance at 1 October 2021 As restated £	Income £	Expenditure £	Transfers in/out £	Gains/ (Losses) £	Balance at 30 September 2022 £
General funds	9,186,902	2,218,467	(2,297,931)	10,245	(515,638)	8,602,045
Restricted funds	1,101,121	563,015	(406,533)	(10,245)	-	1,247,358
	<u>10,288,023</u>	<u>2,781,482</u>	<u>(2,704,464)</u>	<u>-</u>	<u>(515,638)</u>	<u>9,849,403</u>

SUMMARY OF FUNDS – PRIOR YEAR

	Balance at 1 October 2020 As restated £	Income £	Expenditure £	Transfers in/out £	Gains/ (Losses) £	Balance at 30 September 2021 £
General funds	7,644,847	2,433,809	(1,807,916)	121,180	794,982	9,186,902
Restricted funds	1,308,878	97,000	(183,577)	(121,180)	-	1,101,121
	<u>8,953,725</u>	<u>2,530,809</u>	<u>(1,991,493)</u>	<u>-</u>	<u>794,982</u>	<u>10,288,023</u>

17. ANALYSIS OF NET ASSETS BETWEEN FUNDS
ANALYSIS OF NET ASSETS BETWEEN FUNDS - CURRENT YEAR

	Unrestricted funds 2022 £	Restricted funds 2022 £	Total funds 2022 £
Tangible fixed assets	1,039,202	-	1,039,202
Fixed asset investments	5,704,606	-	5,704,606
Investment property	550,000	-	550,000
Current assets	1,860,076	1,247,358	3,107,434
Creditors due within one year	(551,839)	-	(551,839)
	<u>8,602,045</u>	<u>1,247,358</u>	<u>9,849,403</u>

ANALYSIS OF NET ASSETS BETWEEN FUNDS - PRIOR YEAR - As restated

	Unrestricted funds 2021 £	Restricted funds 2021 £	Total funds 2021 £
Tangible fixed assets	1,078,392	-	1,078,392
Fixed asset investments	6,297,104	-	6,297,104
Investment property	550,000	-	550,000
Current assets	1,623,623	1,101,121	2,724,744
Creditors due within one year	(362,217)	-	(362,217)
	<u>9,186,902</u>	<u>1,101,121</u>	<u>10,288,023</u>

18. RECONCILIATION OF NET MOVEMENT IN FUNDS TO NET CASH FLOW FROM OPERATING ACTIVITIES

	2022 £	2021 £
Net (expenditure)/income for the year (as per Statement of Financial Activities)	(438,620)	1,334,298
Adjustment for:		
Depreciation charges	39,190	33,230
Losses/(Gains) on investments	514,298	(724,248)
Dividends, interest and rents from investments	(112,821)	(161,172)
(Increase)/decrease in debtors	(362,552)	69,130
Increase in creditors	189,622	48,162
Net cash (used in)/provided by operating activities	<u>(170,883)</u>	<u>599,400</u>

19. ANALYSIS OF CASH AND CASH EQUIVALENTS

	2022 £	2021 £
Cash in hand	2,081,682	2,114,199
Money Held by Investment Manager	285,208	232,553
Total	<u>2,366,890</u>	<u>2,346,752</u>

20. PENSION COMMITMENTS

The company operates a defined contribution scheme. The pension cost charge for the year represents contributions payable by the company to the scheme and amounted to £198,435 (2021 - £166,500).

21. OPERATING LEASE COMMITMENTS

At 30 September 2022 the total of the Charity's future minimum lease payments under non-cancellable operating leases was:

	2022 £	2021 £
Amounts payable:		
Within 1 year	13,981	13,981
Between 1 and 5 years	24,466	38,447
Total	<u>38,447</u>	<u>52,428</u>

22. RELATED PARTY TRANSACTIONS

5 Trustees of the charitable company received £2,151 (2021 - 1 Trustee - £382) in relation to reimbursed expenses for travel and subsistence incurred as part of their role as trustees. In total, the charitable company paid £30,787 (2021 - £382) to third parties for travel and subsistence of trustees for expenses incurred as part of their role as trustees.

23. PRIOR YEAR ADJUSTMENT

For 1 October 2021, the accounting policy for grants payable recognition changed from the creation of liability on awarding the grant, to recognising the expense as it is incurred and performance conditions are met.

The impact of this prior period adjustment has been to increase net income by £70,864 and reduce grants payable by £414,234. This has increased reserves by £414,234 as at 30 September 2021.

List of Members

Dina Mendes, Pharmacist, Portugal; Israel Olanipekun, Student, Nigeria; Theodore Gouliouris, Consultant, United Kingdom; Jessica Bruerton, Biomedical scientist, United Kingdom; Adekemi Oluyeye, Microbiologist (Clinical), Nigeria; Yen-Zhi Lin, Student, United Kingdom; Laurynas Petrikaitis, Working in industry – pharma, United Kingdom; Shazia Nazir, Pharmacy Technician, United Kingdom; Navin On, Scientific Communications, United Kingdom; Georgia Sermon, Science Communications Executive, United Kingdom; Rachel Kettles, Trainee (other), United Kingdom; Humaira Hussain, Biomedical scientist, United Kingdom; Maria Koliou-mazeri, Infectious Diseases Physician, Cyprus; Chris Danie, Laboratory Practitioner, United Kingdom; Chika Ezeador, PhD Student, Nigeria; Ismaila Damilare Isiaka, Microbiologist, Nigeria; Chinenye EKemezie, PhD Student, United Kingdom; Virginia Hernandez Santiago, Clinical Lecturer, United Kingdom; Conor Doherty, Infectious Diseases Physician, United Kingdom; Eleanor Harvey, Pharmacist, United Kingdom; Adam Nevard, Pharmacist, United Kingdom; Linsey Batchelor, Microbiologist (Clinical), United Kingdom; Chijioke Nsofor, Microbiologist, Nigeria; Dharam Dev, Pharmacist, Pakistan; Joshua Elliott, Infectious Diseases Physician, United Kingdom; Hitesh Tailor, Working in industry – pharma, United Kingdom; Lemonia Ftika, Microbiologist (Clinical), United Kingdom; Nicola Marsh, Pharmacist, Royal United Hospital, United Kingdom; Ashley Chisnell-Davies, Working in industry – pharma, United Kingdom; Frances Edwards, Trainee (ID/Micro), United Kingdom; Judi Lynch, Fellow in Management, Ireland; Ken-Ichi Oinuma, Biomedical scientist, Japan; Melissa Pilbeam, Pharmacist, Australia; Daniella Ross, Infectious Diseases Physician, United Kingdom; Julian Rycroft, Infectious Diseases Physician, United Kingdom; Monsey McLeod, Pharmacist, United Kingdom; Gianluca Pingitore, Dental Practitioner, Italy; Hisham Altayb, Microbiologist, Saudi Arabia; Noura Saif Alnuaimi, Trainee (ID/Micro), United Arab Emirates; Jaggot Chahal, Pharmacist, United Kingdom; Surya Khanna, Microbiologist, United Kingdom; Oluwatosin Orababa, PhD Student, England; Muhammad Saadiq Moolla, Trainee (other), South Africa; Plamen Padeshki, Consultant, United Kingdom; Luis Eduardo Brochet Pineda, Member of public / civil society, Colombia; Liam Wade, Pharmacist, United Kingdom; Thomas Waterfield, Clinical Lecturer, Ireland; Nihal Zeidy, Pharmacist, France; Hena Butta, Microbiologist (Clinical), India; Abhinav Kumar, Consultant, United Kingdom; Hannah Norman-Bruce, Paediatrician, Northern Ireland; Thandar Aye Shein, PhD Student, Myanmar; Emmanuel Elebesunu, Student, Nigeria; Masood Ahmed Tahashildar, Microbiologist, India; Lakshy Guruparan, Specialist Doctor / Consultant, United Kingdom; Nicola Pugliese, Microbiologist, Italy; Hiyam Terfa, Microbiologist (Clinical), Sudan; Vinod Xavier, Consultant, India; Oladapo Akinyemi, Biomedical scientist, Nigeria; Rohit Shinde, Research Fellow, India; Nydia Alejandra Castillo-Martinez, Microbiologist (Clinical), Mexico; Debbie Cook, Student, United Kingdom; Victor Moshia, Microbiologist, Tanzania; Merlin Jonas Wandji Takemegni, Lecturer and PhD Student, Cameroon; Hippal Patel, Biomedical scientist, United Kingdom; Fanta Ann, Laboratory Practitioner, United Kingdom; Abdul Arif Khan, Biomedical scientist, India; Joe Standing, Pharmacist, United Kingdom; Sinalo Mani, Research Fellow, South Africa; Cavan O'Connor, Trainee (ID/Micro), United Kingdom; Nathalie Sadie, Working in industry – pharma, United Kingdom; Tranpriet Saluja, Microbiologist (Clinical), United Kingdom; Melissa Raval, Pharmacist, United Kingdom; Noemita Lagman, Nurse Team Leader, United Kingdom; Ashley Jordan, Biomedical Scientist, United Kingdom; Hannah McCormick, Microbiologist, United Kingdom; Julia Colston, Consultant, United Kingdom; Hisham Ziglam, Infectious Diseases Physician, United Kingdom; Bimal Kumar Agrawal, Consultant, India; Nikolaos Papathanasiou, Infection Prevention Practitioner, Germany; Jasmin Patel, Pharmacist, United Kingdom; Ajay Kumar Prajapati, Laboratory Superintendent, India; Yasmeen Lashari, Microbiologist (Clinical), Pakistan; Raj Regar, Microbiologist, India; Janet Yates, Biomedical Scientist, United Kingdom; Gayatri Jayaraj, Student, India; Folusho Olonipile, Trainee (other), United Kingdom; Ajay Kumar Prajapati, Pharmacist, Malaysia; Rakhi Aggarwal, Pharmacist, United Kingdom; Sophie Hughes, Pharmacist, United Kingdom; S H C Kaushalya De Silva, Microbiologist (Clinical), Sri Lanka; Gemma Staite, Biomedical Scientist, United Kingdom; Abdurakib Abdulrahim, Student, Nigeria; Rajat Ranjan, Pharmacist, India; Jisha John, Pharmacist, India; Dinkar Dubey, General Practitioner, India; Samuel Pearce, Student, United Kingdom; Jane Democratis, Consultant, United Kingdom; William Gaze, Microbiologist, United Kingdom; Amy Jackson, Policy/Government/Civil Service, United Kingdom; Joanne The, Trainee (ID/Micro), Australia; Khaoula Balgouthi, PhD Student, Turkey; Sheetal Goenka, Infection Prevention Practitioner, India; Nipun Verma, Specialist Doctor/Consultant, India; Andrew Chang Kean Wei, Infectious Diseases Physician, Malaysia; Chloe Kirkman, Working in Industry – Pharma, United Kingdom; Claire Cooke, OPAT Specialist, United Kingdom; Okello Emmanuel Onen, Biomedical Scientist, Uganda; Oletantse Tayopa, Pharmacist, Botswana; Gareth Jones, Epidemiologist, United Kingdom; Wai Kien Ng, Trainee (ID/Micro), United Kingdom; Matthew Boutflower, Biomedical Scientist, United Kingdom; Christopher Wagobera, General Practitioner, Uganda; Susan McGladdery, Trainee (Other), United Kingdom; Georgina Muir, Trainee (Other), United Kingdom; Leyla Zahravi, Student, United Kingdom; Adeola Adebisi, Clinical Lecturer, United Kingdom; Suzanne Kelly, Working in Industry – Diagnostics, United Kingdom; Alia Batool, Microbiologist (Clinical), Pakistan; Ahmad Alhasan,

Microbiologist (Clinical), Kuwait; Anmol Aggarwal, Working in industry – pharma, India; Lee Xin Ting, Trainee (other), United Kingdom; Cassie-Jo Layzell, Specialist Nurse, United Kingdom; Nazar Raja, Microbiologist (Clinical), Punjab; Khaoula Balgouthi, PhD Student, Turkey; Aimee Le Maistre, OPAT Specialist, United Kingdom; Wah Wah Hlaing, Microbiologist, United Kingdom; Yako Malcolm, Nurse, United Kingdom; Roisin Foran, Pharmacist, Ireland; Wesam Elbaz, Consultant, Ireland; Alex Peel, Microbiologist (Clinical), United Kingdom; Judith Out, Pharmacist, United Kingdom; Bryony Coupe, Trainee (ID/Micro), United Kingdom; Jas Nahl, Biomedical Scientist, United Kingdom; Ahmed Asiri, PhD Student, United Kingdom; Dami Collier, Infectious Diseases Physician, United Kingdom; Florence Taylor, Nurse, United Kingdom; Saiful Islam, Student, Bangladesh; Farhana Binte Ferdous, Microbiologist, Bangladesh; Sabine Bou-Antoun, Epidemiologist, United Kingdom; Rokeya Ahmed, Research Fellow, Bangladesh; Nada Al Tamtami, Microbiologist (Clinical), Oman; Maria Rodrigues Ribera, Infectious Diseases Physician, Argentina; Aamir Ali Khan, Specialist Doctor/Consultant, Pakistan; Oluwaseun Ogundijo, PhD Student, Nigeria; Gema Rodriguez, Biomedical Scientist, United Kingdom; Tong Sen Yaw, Microbiologist, United Kingdom; Suny Coscione, Trainee (ID/Micro), United Kingdom; Prasun Chakravorty, Trainee (ID/Micro), United Kingdom; Oghenekaro Eghwrujakpor, Microbiologist, Nigeria; Ngwane Ntongwetape, Surgeon, Cameroon; Idemudia Otaigbe, Microbiologist (Clinical), Nigeria; Karen Clark, Health Protection Administrator, United Kingdom; STV Raghavamma, Microbiologist, India; Rohini Wadanamby, Microbiologist (Clinical), Sri Lanka; Gary Macfarlane, Epidemiologist, United Kingdom; Sreeharsha Yeturi, Microbiologist (Clinical), India; Marta Wanat, Research Fellow, United Kingdom; Vikrant Hari Kashyap, Student, United Kingdom; Viji Mohan, Microbiologist (Clinical), United Kingdom; Samar Akbi, Specialist Doctor/Consultant, Algeria; Shalini Dewan Duggal, Microbiologist (Clinical), India; Kulanthaivel Thava Chelvam, Biomedical Scientist, India; Mike Barer, Microbiologist (Clinical), United Kingdom; Nyokabi Kibuka, General Practitioner, Kenya; Usha Lamichhane, Scientific Programme Officer, Germany; Kalliopi Valyraki, Consultant, United Kingdom; Dmitry Titkov, Policy / government / civil service, Finland; Anne-Grete Martson, Research Fellow, United Kingdom; Prabhakar Maurya, Working in industry – pharma, India; Katie Heard, Pharmacist, UK; Alireza Shamaei Tousi, Clinical Scientist, UK; Neda Milevska-Kostova, Pharmacist, Switzerland; Alaeldeen Balal Ahmed, PhD Student, Ethiopia; Phillipa Edmiston, Trainee (ID/Micro), Australia; Imogen Darbhanga, Pharmacist, UK; Medalit Luna, Epidemiologist, Peru; Nicola Norman, Biomedical Scientist, UK; Andrew Timms, Lecturer, UK; Dona Ann Davis, Student, UK; Arindam Dutta, Laboratory Practitioner, India; Oliver Troise, Pharmacist, UK; Tara Hoop, Pharmacist, Canada; Viki Owen, Trainee Clinical Scientist in Microbiology (STP)/ Specialist BMS, UK; Oystein Johansen, Hospital Consultant Microbiologist, Northern Ireland; Tessa Lewis, General Practitioner, UK; Anne Marie Roxburgh, Advanced Biomedical Scientist, UK; George Young, Research Associate, UK; Anushandan Navaratnarajah, Teaching Assistant, Sri Lanka; Polikalipo Kagina, Medical Student, Tanzania; Jabir Ali, PhD Student, Pakistan; Amy Carson, Specialist doctor/ Consultant, UK; Sana Khalid, PhD Student, UK; Jane Keightley, OPAT Specialist Nurse, UK; Gill Jones, Consultant, UK; Aniruddh Shenoy, Trainee, UK; Margaret Logan, Retired Microbiologist, UK; Farah Aydin, Research Fellow, Turkey; Nizam Damani, Associate Medical Director of Infection Prevention and Control (IPC), UK; Usama Hantour, Trainee ID/Micro, Egypt; Fiona Jordan, Biomedical Scientist, Northern Ireland; Kenneth Ejigeme, Student, UK; Mohammad Ruhul Amin, PhD Student, Canada; Muhammad Abhi Purnomosidi, Veterinary Practitioner, Indonesia; Michael Davies, Pharmacist, UK; Alain Nizigiyimana, Infection Prevention Practitioner, Belgium; Chaturika Thamara Hapuarachchi, Consultant Microbiologist, UK; Ankit Gaur, Clinical Pharmacologist, India; Paul Osua, Doctor, Mexico; Andrzej Biilan, Specialist Doctor/ Consultant, Poland; Muskan Tiwari, Student, India; Jahan Saeed Mallick, Trainee (other), Germany; Hafsat Alabere, Microbiologist, Nigeria; RASUL ALY, First Responder and Response Team Member, UK; Igor Sychev, ID Physician, Russia; Salman Khan, Medical Student, Pakistan; Fadelalla Elmozoghi, Medical Student, Libya; Rohul Amin, Epidemiologist, Bangladesh; Clare Williamson, Pharmacist, UK; Laura Fawdon, OPAT Specialist Nurse, UK; Maryanna Tavener, Trainee, UK; Fabian Ogbonne, Principal Research Officer, Nigeria; Mienye Bob-Manuel, Consultant clinical microbiologist, Nigeria; Fabiola Defacio, Pharmacist, Brazil; Adrienn Kis, Senior Medical Writer, UK; Sarah Bourne, Consultant, UK; Suhrab Sayfi, Senior Clinical Pharmacist, UK; Triveni A G, Assistant Professor, India; Charlotte Ann Gulliver, Student, UK; Nathalia Abichabki, PhD Student, Brazil; Mary Ann Imperial, OPAT Specialist Nurse, UK; Bello Temitope, Lecturer, Nigeria; Ruth Mathers, Paediatrician, UK; Rebecca Parr, Assistant Study Coordinator, UK; Gessica Milani Carneiro, Pharmacist, Portugal; Shabnil Prasad, Specialist Physician, Fiji; Om Saswat Sahoo, Student, West Bengal; Paradzai Innocent Najazi, Student, Zimbabwe; Mindy Engevik, Biomedical Scientist, USA; Amy Moore, OPAT Specialist, UK; Pradeep Kumar, Microbiologist, India; Rajeev Singh, Policy/ Government/Civil Service, India; James Delaney, PhD Student, UK; Hasnain Sajjad, Student, Pakistan; Sheetal Sundeep, Consultant Microbiologist, UK; Michael Francisco, Microbiologist, Philippines; Ameerah Racman, Student, Philippines; Concepción Segura, Clinical Scientist, Spain; Alzhraa Mohamed, PhD Student, Egypt; Saanya Yadav, Student, India; Hadi Jamalian, Nurse Prescriber, Iran; Peter Balogun, Microbiologist, Nigeria; Abby Midgley, Biomedical Scientist, UK; Japhet Erasmus Aisoni, Microbiologist, Nigeria; Umar Jafa, Laboratory Practitioner,

Nigeria; Ibrahim Musa Sani, Pharmacist, Nigeria; Jessica Jinks, PhD Student, UK; Prabhu Rajendran, Consultant Paediatrician, UK; Aldo Proietti-Junior, Microbiologist (Clinical), Brazil; Brian Conlon, Microbiologist, USA; Junaidu Abubakar, Student, Nigeria; Marie Francoise Gros, Working in industry – diagnostics, Rhone; Dorcas Egunjobi, Microbiologist (Clinical), Nigeria; Peter Anthony Oyom, Laboratory Practitioner, UK; John Navis, Pharmacist, UK; Mohammed Ali, Microbiologist, Ethiopia; Cassandra Hoyland, Science Communications, UK; Vicky Pollington, Science Communications, UK; Krupa Ann Sunil, Pharmacist, India; Peter Craggs, Biomedical Scientist, UK; Oleh Khomko, Surgeon, Ukraine; Sarah Appleby, Trainee, UK; Maimua Damu, Trainee (ID/Micro), United Arab Emirates; Shay Khan, Pharmacist, UK; Sarah Wood, Clinical Scientist, UK; Ben Cave, Director, Public Health & Environment, UK; STELLA ENYINNAYA, Consultant, Nigeria; Annie Justh, Microbiologist, Sweden; Eithar Karrar, Microbiology lecturer, Sudan; Aleksandra Choporova, Clinical Scientist, Ukraine; Justin Williamson, Consultant, Australia; Shahab Ahmad Khan, Microbiologist, Pakistan; Maria Jose Ruiz Alvarez, Microbiologist, Italy; Solomon Oranusi, Microbiologist, Nigeria; Ali Awais Malik, Medical Registrar, Saudi Arabia; Varun Shamanna, PhD Student, India; Hardy Schweigel, Clinical Trial Manager, Germany; Chidiebere Obi, Research Fellow, Nigeria; Janiece Glover, Student, USA; LUCY NYANGAU, Student, KENYA; Jagatheesa Naidoo, Member of Public/Civil Society, South Africa; Louise Catterall, Biomedical Scientist, UK; Sevaram Singh, PhD Student, India; VISHNU VANDANA WADDEPALY, Microbiologist, India; Maham Rasheed, GP, Kyrgyzstan; Sumit Rai, Microbiologist (Clinical), India; Sarah Thomas, Biomedical Scientist, UK; Shaun Wake, Working in industry – diagnostics, UK; Yaw Twum-Danso, Pharmacist, UK; Elsie Chidebe, Working in Industry – Pharma, Nigeria; Orode Aniejurengbo, Associate Lecturer, UK; Mayi Mayega, Pharmacist, Uganda; Aswathy P, Pharmacist, India; Sarah Weller, Biomedical scientist, UK; Matthew Colbert, Nurse, UK; Daniel Stevenson, Trainee (ID/Micro), UK; Breanna Dixon, PhD Student, UK; Nino Butskhrikidze, Georgia; Moe Abouzari, ID Physician, USA; Abdul Rehman, Student, Pakistan; Barbara Weinhardt, Microbiologist (Clinical), UK; Rachel Meade, Student, UK; Jamie Whysall, Nurse, UK; Yuri Protaschik, Trainee (ID/Micro), Northern Ireland; Susanna Davis, Consultant, UK; Wynand Smythe, Clinical, Pharmacist, South Africa; Katie Lawther, PhD Student, Northern Ireland; Steven Kemp, Research Fellow, UK; Rebecca Parr, Assistant Study Coordinator, UK; Gessica Milani Carneiro, Pharmacist, Brazil; Aggie Grand, Nurse Prescriber, UK; Stephen Igwe, Medical Student, Nigeria; Liam Brown, Comms, UK; Rachel Pitt, Biomedical Scientist, UK; Davide Loliva, R&D Associate, UK; Harsha Perera, Microbiologist (Clinical), UK; Luke Turner, Clinical Scientist, UK; Abiola Odeyinka, Specialist Doctor/Consultant, UK; Isatou Sarr, Scientific Officer, Gambia; Gillian Kiely, Pharmacist, UK; Geneva Wilson, Epidemiologist, USA; Alice Binns, Pharmacist, UK; Florence Bradshaw, Student, UK; Rayna Koshy, Medical Student, UK; Sarah Fagan, Pharmacist, Ireland; Jagan Nathan, Pharmacist, India; Tanveer Ahmed, PhD Student, India; Dimple Kasana, Director, India; Justina Spyrka, Biomedical Scientist, UK; Maria Rose Domingo Sananes, Lecturer, UK; Md. Liton Rana, Student, Bangladesh; Izahiuwa Iredia, Student, UK; Raman Muthusamy, Project Manager and Professor, India; Renata Do Couto Pereira, Infection Prevention Practitioner, UK; Sajjad Ali, Infectious Diseases Physician, Pakistan; Sonali Biswas, Student, India; Sumana Saha, MSc microbiology, India; Amalita Das, Student, India; Ritika Chakraborty, Student, India; NAMRATA SAMANTA, Student, India; Shatarupa Biswas, Student, India; Udisha Sarkar, Student, India; Runa Khamaru, Student, India; Dishani Saha, Microbiologist, India; Marwan Abdullah, Pharmacist, Iraq; Elisa Costa, Consultant, Scotland; Sandra Mitchell, Biomedical scientist, Airdrie; Billie Caceda, Microbiologist (Clinical), Ireland; Rebecca Taylor, Lead Pharmacy Technician – Antimicrobials, UK; Rehab Ahmed, Pharmacist, Saudi Arabia; Mala Shah, Pharmacist, Ireland; Janis Romanopoulos, PhD Student, United Kingdom; Daniel Mekonnen, Microbiologist, Ethiopia; Hemali Bedi, Managing Editor, England; Kirsty Goudar, Microbiologist, UK; Benedicta Ruff, Infectious Diseases Physician, USA; Fatima idress, Laboratory Practitioner, Sudan; Dr Junaid Naeem Rph, Pharmacist, Pakistan; MANISH CHOWDHARY, PhD Student, INDIA; Vinay Mohan Pathak, Microbiologist, India; Gulalai Bangash, Pharmacist, Pakistan; Akinwunmi Akinleye, Medical student, Nigeria; Ansh Modak, Student, India; Chinedu Anele, Student, Nigeria; Suhail Sarwar, Lead Antimicrobial Pharmacist, Wales; Andrew Smith, Microbiologist (Clinical), UK; Marvellous Asika, Medical student, Enugu; Atharva Thosar, Student, India; Agnibha Chattopadhyay, Student, India; Colin Hudson, Clinical Scientist, United Kingdom; Michael Riste, Infectious Diseases Physician, UK; Ashleigh Myall, PhD Student, UK; Shobha Luxmi, Consultant, Pakistan; Paul Jones, Biomedical scientist, London; Callum Ryan, Pharmacist, Ireland; Emily Freeman, Student, UK; Getnet Enyew, Specialist Doctor / Consultant, Bahirdar; Shweta Kuba, UK; Rowan Green, PhD Student, United Kingdom; Michael Bottery, Researcher. UK; Isabel Sze Wing Fok, Pharmacist, UK; Giorgia Sulis, Biomedical scientist, Canada; Professor Regan, Epidemiologist, United Kingdom; Gustavo Goldman, Professor, Brazil; Blair Merrick, Trainee (ID/Micro), UK; Michele Bastos, Pharmacist, Brasil; Abhishek Chatterjee, Microbiologist, India; Priyanka Bhowmik, Assistant professor, India; Saptarshi Chatterjee, Microbiologist, India; Manoj Kumar Singh, Associate Professor, India; Hindol Ray, Student, West Bengal; Emma Mewse, Nurse, UK; Astrid Gerrard, Pharmacist, UK; Pavani Kotala, Microbiologist, United Kingdom; Sampurna Saha, Microbiologist, India; Swayam Satope, Student, India; Mrunal Shastri, Student, India; Sheku J. Idriss, Pharmacist, Sierra Leone; Siobhan O'Brien, Microbiologist, Ireland; Mehuli Das, Student, West Bengal; Nicola Rideout, Working in industry – pharma,

England; Melissa Chengalroyen, Microbiologist (Clinical), South Africa; Divya Tiwari, Biomedical scientist, United Kingdom; Kiranmai Bhatt, Trainee (ID/Micro), UK; Rachael Rodger, Pharmacist, UK; Halida Kuduzovic, Biomedical scientist, Malta; Muhammad Hammad, Pharmacist, UAE; Clara Tam, Pharmacist, Conwy; Paulina Grzegorzolka, Pharmacist, UK; Caroline Walker, Pharmacist, UK; Stephen Page, Veterinary Practitioner, Australia; Rhiannon Robinson, Pharmacist, UK; Sian Boots, Epidemiologist, UK; Omar Elyan, Microbiologist, Egypt; Amina Obradovic Balihodzic, Microbiologist, Bosnia and Herzegovina; Soham Gajre, Veterinary Student, India; Sarah Gerver, Epidemiologist, United Kingdom; Eniola Alex, Pharmacologist, Nigeria; Rebecca Guy, Epidemiologist, UK; Brendan Kelly, Infectious Diseases Physician, USA; Frederick Andaya, OPAT Specialist, United Kingdom; JUWON AFOLAYAN, Student, United Kingdom; Jonny Williams, Biomedical scientist, United Kingdom; Leonardo Nieto-Aponte, Microbiologist, Mayo; Yetunde Ogunpitan, Biomedical scientist, Nigeria; HRISHITA SAHA, Student, India; Namrata Poddar, Student, India; Wilson martin aguero echeverria, Infectious Diseases Physician, Paraguay; Heather Felgate, Microbiologist, UK; Arwa Musa, Microbiologist, Sudan; Ravi Kumar Konda, Research Fellow, INDIA; Sarah Toplis, Pharmacist, UK; Shadia Ahmed, Research Fellow, England; Pushpa Saajan, Microbiologist, United Kingdom; Gemma Beech, Nurse Prescriber, UK; Martin Laird, General Practitioner, UK; Lindsay Pullan, Nurse Prescriber, UK; Axel Hamprecht, Microbiologist (Clinical), Germany; Zackery Bulman, Pharmacist, USA; Margaret Lubwama, Microbiologist (Clinical), Uganda; Carol Philip, Pharmacist, UK; George Gyamfi-Brobbe, Clinical Scientist, UK; Shahmeen Ali, Healthcare Scientist, UK; Laura Diaz Saez, Structural biology, UK; Laimin Makalo, Paediatrician, Gambia; Zahra Sadouki, PhD Student, UK; Rina Desai, Healthcare Scientist, UK; Ruhi Siddiqui, Head of Standards Unit, UK; Rahul R, PhD Student, India; Funmilayo Ijadowole, Policy / government / civil service, Nigeria; Bukola Okesipe, Biostatistician, Nigeria; Andrea Falzon, Pharmacist, Italy; Nirlep Agravedi, Pharmacist, England; Sheriffdeen Idowu, Microbiologist, Nigeria; Moses Otunla, Student, Nigeria; Bekir Caglar Celikkaya, PhD Student, UK; Ben Tomlinson, Trainee (ID/Micro), UK; Mauricio Arias, Consultant, UK; Hannah Shotnes, Veterinary Practitioner, UK; Delyth Hearne, Pharmacist, UK; Tomer Lamhoot, General Practitioner, UK; Olubusayo Adewole, Research Fellow, Nigeria; Nkechi Maduekwe, Specialist Doctor / Consultant, Anambra; Emmanuel Opadokun, Student Nigeria; Paul Beckett, Microbiologist (Clinical), UK; Joshua Adeyemi, Student, Nigeria; Christine Pender, Pharmacist, Renfrewshire; Musa Garbati, Consultant, Nigeria; Elita Jauneikaite, Research Fellow, United Kingdom; Aisosa I lyoha, PhD Student, UK; Stuart Brown, Pharmacist, Durham; Daniel Parkes, Science Communications Executive, UK; Adam Bendall, Scientific Communications and Events, United Kingdom; Ross Leslie, Science Communication Executive, Lincolnshire; Peter Whawell, CEO, Kent; Alice Liu, Pharmacist, Gloucestershire; Sam Whybrow, Nurse, Essex; Chloe Rodic, Graphic Designer, UK; Awilly Aden Ibrahim, UK; Louise Binnie, OPAT Specialist, UK; Sarah Williams, UK; Mohana Marathe, Student, India; Rachel Pike, Biomedical scientist, UK; Jennifer Ward, Senior Podiatrist, Kilkenny; Avril Tucker, Pharmacist, Bridgend; Graciela Sluga, Consultant, UK; Olaronke Akinpelu, Microbiologist, Nigeria; Michelle Borthwick, Biomedical scientist, Chorley; ITOHOWO FABIAN, Laboratory Practitioner, Nigeria; Sonal Saxena, Microbiologist (Clinical), India; Drosos Karageorgopoulos, Consultant, United Kingdom; Reham Khedr, Infectious Diseases Physician, Egypt; Dua'a Ghabashineh, Microbiologist, Jordan; Miroslav Sirota, Non-clinical Lecturer (Reader in Psychology), United Kingdom; Mohamed Achouri, Medical student, Tunisia; Yara Badereddin, Contact tracing practitioners, Scotland; Osman ali, Pharmacist, UK; Nicola Harrap, Pharmacist, Nottinghamshire; Godwin Obande, Microbiologist, Nigeria; Folake Lanlehin, Microbiologist (Clinical), Nigeria; VIBHOR TAK, Microbiologist (Clinical), RAJASTHAN INDIA; Zannatul Ferdous Miftah, Student, South Glamorgan; Anna Karin Belfrage, Project coordinator, Sweden; Claire McMurray, Clinical Scientist, United Kingdom; Elaine Fernandes, Pharmacist, India; Miguel Alexandre Lucio, Working in industry – pharma, United Kingdom; Christine Mackay, Working in industry – pharma, United Kingdom; Hala Al Hinai, Microbiologist, United Kingdom; Kingsuk Misra, General Practitioner, India; Luã-sa Zacharias, Microbiologist, Brazil; Ali Omrani, Infectious Diseases Physician, Qatar; Ines Moura, Research Fellow, Yorkshire; Sin Tung Yu, Pharmacist, Derbyshire; Jesuferanmi Igbini, Pharmacist, Nigeria; Parisa Pordelkhaki, PhD Student, United Kingdom; Vishal Patel, Specialist Doctor / Consultant, United Kingdom; Gurmeet Dhanoa, PhD Student, UK; Kirsty Dodgson, Clinical Scientist, Greater Manchester; Aileen Boyd, Consultant, London; Roshan Khatri, Microbiologist, United Kingdom; Dr Vaishali Gokahle, Microbiologist (Clinical), INDIA; Sean Whelan, Trainee (ID/Micro), Ireland; Carolin Kobras, Research Associate, United Kingdom; Kevin Wangokho, Pharmacist, Kenya; Tesleem Ibrahim, PhD Student, Northern Ireland; Katrina Blackmore, Microbiologist (Clinical), North Yorkshire; Muhammad Tariq Khan, Pharmacist, Pakistan; Emily Fernandes, Pharmacist, England; Anu Viljanen, OPAT Specialist, London; Cátia Caneiras, Pharmacist, Portugal; Ruben de Dios Barranco, Research Fellow, Middlesex; Brakemi Egbedi, PhD Student, Ireland; Majella Warnock, Pharmacist, N-Ireland; Caitlin Edlington, Specialist Nurse, West Yorkshire; EUNICE FOSUAA-KYEI, General Practitioner, GHANA; Mivanyi Kadala, Infectious Diseases Physician, UK; Salim Abubakar, Microbiologist, Nigeria; Fatima Ulhuq, Trainee (ID/Micro), Scotland; Damla Cetinkaya, Microbiologist (Clinical), Turkey; SAGAR CHANDRAKAR, Microbiologist (Clinical), INDIA; Asma Yagoub, Student, Sudan; Joseph Estopen, Nurse, United Kingdom; Edel Hyland, Biomedical

scientist, Northern Ireland; JIGYASA SINGH, Microbiologist, UTTAR PRADESH; Sayantan Ghosh, Clinical pharmacologist, India; Hannah Kershaw, Pharmacist, UK; Elisha Zafar, Pharmacist, UK; AnĀĳlia Carmo, Microbiologist (Clinical), Portugal; Connor Wood, Post-doctoral Researcher, Republic of Korea; Clare Logan, Infectious Diseases Physician, United Kingdom; leeanne stewart, Pharmacist, Antrim; Lyndsey Rignall, Nurse, UK; Mercy Takuwa, Biomedical scientist, Uganda; sophie lawrence, OPAT Specialist, UK; Joanna Allen, Consultant, United Kingdom; june james, OPAT Specialist, United KINGDOM; Eulogio Coz, Surgeon, Philippines; Cristina Suarez, Microbiologist (Clinical), UK; Maisie-Jane Fry, Pharmacist, Derbyshire; Mal Gribbon, Pharmacist, N Ireland; Meera Jalota, Pharmacist, UK; Borbala Zsigmond, Specialist Doctor / Consultant, UK; Jenniferth Aviles, Nurse, UK; Karen McCleary, OPAT Specialist, United Kingdom; Clare Sander, Consultant, UK; JULIO ROEL PAGAN, Nurse, UK; John Gladney, OPAT Specialist, UK; Innocent. Dunstan, OPAT Specialist, London; Dr Vinayaha Sooriyar Udayachandren, Microbiologist (Clinical), UK; Marian Rehak, Working in industry - diagnostics, UK; Constance Baker, OPAT Specialist, UK; Stacy Todd, Consultant, UK; Wuditu Serbessa, OPAT Specialist, UK; Davina Sharma, Infectious Diseases Physician, UK; Murjanatu Salihu Gulmah, Microbiologist, Nigeria; Diana Kinyua, Research Fellow, Kenya; Alexandra Bramley, Trainee (ID/Micro), UK; Charlotte Richards, Pharmacist, UK; Thamara Nawimana, Consultant, UK; Ibrahim Abdulrasul, Clinical Lecturer, Nigeria; lisa hollins, OPAT Specialist, UK; Augustine Aghama, Laboratory Practitioner, Nigeria; Hiie Soeorg, Research Fellow, Estonia; Ndege Daudi, Laboratory Practitioner, Kenya; Amer Almaghrabi, F2 Doctor, United Kingdom; Joseph Spencer-Jones, Pharmacist, UK; Ben Freeman, OPAT Specialist, UK; Umar Hassan, Microbiologist (Clinical), Nigeria; Chris Dugan, Consultant, UK; Evangelos Balanikas, Nurse, Attica; Rakan El-Hamad, Microbiologist (Clinical), Jordan; Patricia Carroll, Specialist Nurse, Offaly; Uzo Akabogu, Student, UK; Maria Hassan, Pharmacist, Pakistan; Usman Adekanye, Epidemiologist, Nigeria; Alade Tolulope, Microbiologist (Clinical), Nigeria; Taoran Fu, PhD Student, UK; Kate Davey, Nurse, UK; Grace Olusegun, Biomedical scientist, Lagos; Esther Otegbola, Biomedical scientist, Nigeria; SAISREE SANGIREDDY, Student, India; Carmel Guy, OPAT Specialist, UK; Kehinde Kolapo, Microbiologist, Nigeria; Callum Ryan, Infection Prevention Practitioner, Limerick; Rajan Paudel, Medical Student, Nepal; Maher Alqurashi, Microbiologist, Saudi Arabia; Tomisin Adebhari, Student, Oyo; Ayush Gupta, Microbiologist (Clinical), India; Fatemeh Ahangarkani, Clinical Scientist, Iran/ Mazandaran; Mangalanath Udukala, Microbiologist, UK; sarah osmond, Nurse Prescriber, UK; Daniel Ng, Trainee (other), UK; Julie Griffin, OPAT Clinical Support Worker, UK; Dr.Akshay Shelke, PhD Student, India; Andrew GILBERT, Nurse, United Kingdom; Azul Zorzoli, Trainee (other), Scotland; Nuthan Tom, Trust Spr In Haematology, United Kingdom; May Thazin Aye, Myanmar; Tom Lewis, Consultant, UK; Victoria Whitehead, OPAT Specialist, UK; Reema Carty, OPAT Specialist, UK; Susan Githii, Microbiologist (Clinical), Kenya; Simon Moore, Microbiologist, Kent; Abraham Okoibhole, Pharmacist, Essex; ROGELIO TINAJERO PIZANO, Epidemiologist, Mexico; Susan Egbert, Student, Manitoba; Vida Amponsah-Ocrah, OPAT Specialist, UK; Samita Majumdar, Consultant, United Kingdom; Ryan Kean, Microbiologist, Scotland; Olayinka Osulale, Microbiologist, Nigeria; Ahmed Sami Salman, Microbiologist (Clinical), Iraq; Claire Shepherd-Cutler, Biomedical scientist, UK; Victoria Coleman, Nurse, UK; shameema khan, Microbiologist (Clinical), SOUTH AFRICA; Trish Turton, Specialist Nurse, UK; Richard Watkins, Infectious Diseases Physician, Ohio; Nazym Iskakova, PhD Student, Kazakhstan; Harsimran Kaur, Microbiologist (Clinical), India; Liyanage Shamithra Madhumali Sigera, Trainee (ID/Micro), United Kingdom; Michaelene Holder-March, Student, United Kingdom; Alpana Mohta, General Practitioner, India; Ameer Shajahan, Pharmacist, India; Sam Lyvannak, Paediatrician, Cambodia; Bernadette O'Riordan, Pharmacist, UK; Arooj Abid, Pharmacist, Pakistan; Nkechi Maduekwe, Trainee (ID/Micro), Nigeria; Saoussen Oueslati, Microbiologist, France; TĀĳrkan Toka Āĳzer, Microbiologist (Clinical), Turkey; Rod Hulme, Working in industry - medical devices, UK; Ngozi Adenekan, Biomedical scientist, Nigeria; Maria Dimopoulou, Microbiologist (Clinical), Germany; Alice Goodwin, Pharmacist, UK; Russell Dacombe, Biomedical scientist, UK; Sara Ibrahim, Pharmacist, Egypt; muhammad khalid Iodhi, Pharmacist, UK; Federico Nicola, Microbiologist, Argentina; Alexander Wunderlich, Medical student, Germany; Pasco Hearn, Consultant, UK; Sharon Jose, Microbiologist (Clinical), UK; Sarah M Kalufyanya, Community Engagement Assistant, Zambia; Dilruba Ahmed, Laboratory Practitioner, Bangladesh; Rostyslav Marushko, Paediatrician; Nathalie Roberts, Pharmacist, UK; Alfred Amambua-Ngwa, Biomedical scientist, Gambia; Lucy Ellis, Nurse, United Kingdom; Rachael Brindle, Nurse Prescriber, UK; Joji Mathai Simon, Clinical Lecturer, United Kingdom; SANKET SURKULE, Student, INDIA; Dr jainendra Nishad, Microbiologist (Clinical), Uttar Pradesh; Ivana Such ĀĳnkovĀĳi, Student, Czechia; Ai-Nee Lim, Pharmacist, UK; Safaa Eissa, Junior doctor, UK; Kome Otokunefor, Microbiologist, Nigeria; Samuel Omotayo Iyanda, Student, Nigeria; Alina Hristu, Trainee (ID/Micro), UK; Gosia Bezwinska, Student, UK; Mojisola Clara Hosu, Microbiologist, South Africa; Monette Saguindan, OPAT Specialist, UK; Gilles Brackman, Working in industry - pharma, Belgium; Jerome Walker, Microbiologist (Clinical), Jamaica; Heather Gray, Research Fellow, Lanarkshire; aida krajnc, Pharmacist, UK; IGWE EMMANUEL MICHAEL, Biomedical scientist, NIGERIA; Hithesh Kumar, Research Fellow, Karnataka; Victoria Savage, Head of Biology, United Kingdom; Doug Izzard, Pharmacist, UK; Luke Moore, Infectious Diseases Physician, London; Rupesh Chikhale, Biomedical scientist, UK; Venkateswarlu

Yarlagadda, Assistant Professor, India; Andile Faya, Biomedical scientist, South Africa; Donald Morrison, Microbiologist, UK; Mikhail Scherbakov, Working in industry - pharma, Russia; Thomas Locke, Infectious diseases/ medical microbiology SpR, UK; QUINTEN CLARKSON, Specialist Nurse, UK; Braira Wahid, Biomedical scientist, Australia; Olarinde Olaniran, Biomedical scientist, Nigeria; Rana Mohamed, Student, Sudan khartoum; Fadia Alsheikh, Pharmacist, United Kingdom; Paulina Carreño Párez, Infectious Diseases Physician, Distrito Federal; Alidah ANIAMBOSSOU, Microbiologist, IVORY COAST; Zeljka Krpetic, University lecturer, United Kingdom; LEKSHMI R, Medical student, India; Laura MacLachlan, OPAT Specialist, UK; Jack Homer, PhD Student, UK; Joe Sweeney, Biomedical scientist, United Kingdom; agnieszka zacharzewska, Nurse, UK; RANJANA MISHRA, PhD Student, India; RIZAL HUSAINI RAZALI, Pharmacist, MALAYSIA; Santosh Kumar Yadav, Microbiologist, Nepal; SimranMore, Student, United Kingdom; Abolaji Atomode, Infectious Diseases Physician, UK; Kehinde ADEDIRAN, Lecturer/Researcher, Nigeria; Debby Muriithi, Student, UK; Farzaneh Khodaei, Microbiologist (Clinical), Iran; Caroline Jarvis, Student, UK; Katharine Stott, Clinical Lecturer, Merseyside; Dr SAMIYAH TASLEEM, Microbiologist, Pakistan; Dooshima Nevkaa, PhD Student, United Kingdom/Europe; Teresa Conceicao, Post doctoral resercher, Portugal; Deepak Kumar, Infectious Diseases Physician, Rajasthan; gayatri takekar, Medical student, Maharashtra; Rashi Sharma, Student, Delhi; Dona Wilani Dynatra Subasinghe, Clinical Lecturer, UK; amarjeet kaur, Microbiologist (Clinical), UK; Semasimange Midunil Madhushanka, Trainee (other), Sri Lanka; Maisie Palmer, PhD Student, United Kingdom; Giovanni Firpo, Trainee (other), UK; Lily Riordan, PhD Student, Scotland; Holly Acford-Palmer, PhD Student, United Kingdom; Douglas Robinson, PhD Student, Scotland; Shaimaa Ibrahim, PhD Student, UK; Victoria Chris, PhD Student, UK; Sodiq Yusuff, Consultant, Abuja; Neal Russell, Paediatrician, UK; Matthew McCracken, Student, United Kingdom; Uzoma Igwe, PhD Student, Nigeria; Derek Cocker, Infectious Diseases Physician, United Kingdom; Karen Villalobos Arriagada, Epidemiologist, Chile; Mollie virgo, PhD Student, UK; Nicole Loeven, Microbiologist (Clinical), USA; MUHAMMAD UMAR ZAFAR KHAN, Microbiologist, Punjab; Lorna Flintham, PhD Student, UK; Hassan Al-mana, PhD Student, United Kingdom; Felix Vega, Student, UK; Aleksandra Postnikova, Paediatrician, Vitsebsk Province; SWASTI RAWAL, PhD Student, Austria; Darakhshan Ahmed, Microbiologist, London; Nathan Moore, Microbiologist, United Kingdom; Daniel Oduneye, Student, Nigeria; Elizabeth TAYLER, Policy / government / civil service, Egypt; Ujjal Das, Student, India; Jawahir Mokhtar, Microbiologist (Clinical), Makkah; Dana Itani, Microbiologist, United Kingdom; Houssein Eddine Mansouri, Specialist Doctor / Consultant, Algeria; Dr Bernd Neumann, PhD Student, Austria; Ianca Albuquerque, PhD Student, Brazil; Mr Kharka Bdr Bhattarai, Pharmacist, Butan; Tara Hoop, Pharmacist, Canada; Professor Xin Zhao, Clinical Lecturer, Canada; Mr Ron Diamond, Other - President, Canada; Ximena Fernandez, Student, Chile; Dr Mariam Abdelsalam, Student, Egypt; Amr Kashef, Infectious Diseases Pharmacist, Egypt; Edlawit Getachew, Research Fellow, Ethiopia; Emilie Dewever, Veterinary Practitioner, France; Dr Veronique Vernet Garnier, ID/Micro Trainee, France; Frank Mattes, Consultant, Germany; Nelson Masota, PhD Student, Germany; Dr Alex Owusu-Ofori, Microbiologist, Ghana; Emmanuel Sarkoide, Pharmacist, Ghana; Ms Elina Eleftheris Pliakos, Student, Illinois; Shiva Shankari, Microbiologist (Clinical), India; Dr Shingini Sharma, Other - Joint Director, India; Dr Anand Manoharan, other - Director of Research, India; Dr Urvashi Tiwari, Specialist Doctor / Consultant, India; Ms Kajal Gupta, Student, India; Dr Juby O Chacko, Pharmacist, India; Kannan, Research Fellow, India; Dr Shruthiva Santh, Clinical Lecturer, India; Neilay Bhalerao, Student, India; Sameer Bawankule, Paediatrician, India; Gagan Dhawan, Biomedical scientist, India; Uma Dhawan, Biomedical scientist, India; Amit Upadhyay, Consultant, India; Alaka Sahoo, PhD Student, India; Raj Sharma, Clinical Lecturer, India; Sayli Gore, Pharmacist, India; Dr Naveen Bansal, Clinical Lecturer, India; Dr Yashik Bansal, Clinical Lecturer, India; Nisha Sharma, Clinical Lecturer, India; Dr Jisha Thomas, Pharmacist, India; Dr. Amit Keshari, Clinical Lecturer, India; Fiona Leonard, Pharmacist, Ireland; Nicola Pugliese, Research Fellow, Italy; Alessia Savoldi, Consultant, Italy; Alessandro Visentin, Trainee (ID/Micro), Italy; Maria Elena De Rui, Trainee (ID/Micro), Italy; Raveed Khan, Clinical Lecturer, Jamaica; Adam Leversuch, Pharmacist, Jersey; Kevin Kariuki, Microbiologist, Kenya; Dr Jael Obiero, Research Fellow, Kenya; Morrison Kabiru, Other - Medical Officer, Kenya; Wafaa Jamal, Microbiologist (Clinical), Kuwait; Elizabeth Ashley, Microbiologist (Clinical), Laos; Muhammad Luqman Nordin, Clinical Scientist, Malaysia; Mohd Farhan Haif Reduan, Clinical Lecturer, Malaysia; Erkihun Woldegiorgis, Clinical Lecturer, Malaysia; Chris Tan, Student, Malaysia; Usman Abubakar, Senior Lecturer, Malaysia; Dr KIFelipe Guerrero, Other - Director, Mexico; Niroj Amatya, Clinical Lecturer, Nepal; Karlijn Hofstraat, Junior Researcher, Netherlands; Dr Coen van Hasselt, Clinical Lecturer, Netherlands; Vuong Le, Research Fellow, New Zealand; Godwin Pius Ohemu, Other - Executive Administrative Officer, Nigeria; Mr Ayobami Samuel Owoyemi, PhD Student, Nigeria; Ms Ayobami Christiana Olawusi, Student, Nigeria; Musa Galadima, Clinical Lecturer, Nigeria; Chiamaka Jibuaku, Research Fellow, Nigeria; Kenneth Egwu, Student, Nigeria; Victoria Adetunji, Consultant, Nigeria; Opeyemi Akindele, Other - Founder, Instapharm Healthcare and Director, Instapharm Research Institute & System, Nigeria; David Oke, Research Fellow, Nigeria; Dr Calistus Kenechukwu Okechukwu, General Practitioner, Nigeria; Mr Asogwa Chikodili Nestor, Laboratory Practitioner, Nigeria; Mr Akinfolarin Emmanuel Akinbulumo, Pharmacist, Nigeria; Oyindamola Oteju-sola, PhD Student, Nigeria; Elohor

Okpako, Microbiologist, Nigeria; Ms Fatimah Olabisi Oyedeji, Pharmacist, Nigeria; Ogunsakin Seyi, Student, Nigeria; Jeremiah Achimugu, Laboratory Technician, Nigeria; Rabi Adamu Suleiman, Veterinary Practitioner, Nigeria; Phyllis Steele, Microbiologist (Clinical), Northern Ireland; Tore Taksdal, Consultant, Norway; Ms Nokukhanya Patience Kodzai, Research Fellow, Pakistan; Dr Basildon Sultan, Other – Trainee, Pakistan; Zul Kamal, Clinical Lecturer, Pakistan; Christine Joy Timario, Graduate Student, Philippines; Jeta Lamaj, Infection Prevention Practitioner, Qatar; Dr Mohammed Hassan Alsowailam, Veterinary Practitioner, Saudi Arabia; Dr Philile Donna Bongekile Hlengwa, Other – Hospital Clinical Manager, South Africa; John Sloman, Retired GP / Part time volunteer teacher, Spain; Asma AbdAl Mageed, Microbiologist, Sudan; Maria Verena Elzi, Microbiologist (Clinical), Switzerland; Lina Perekhoda, Pharmacist, Ukraine; Vadim Zubkov, Clinical Lecturer, Ukraine; Kal Cave, Consultant, United Kingdom; Mary Eva Regan, Pharmacist, United Kingdom; Olivia Gallagher, Pharmacist, United Kingdom; Rahila Chaudhry, Biomedical Scientist, United Kingdom; Annsar Warraich, Research Fellow, United Kingdom; Irasha Harding, Microbiologist (Clinical), United Kingdom; Rachel Williams, Other – Regional Vaccine Trials Manager, United Kingdom; Natalie Tegama, PhD Candidate, United Kingdom; Jordan Skittrall, Clinical Lecturer, United Kingdom; Vancessa Crowle, Student, United Kingdom; Jaisi Sinha, Consultant, United Kingdom; Clemency Nye, Infectious Diseases Physician, United Kingdom; Kanchan Dhamija, Consultant, United Kingdom; Mr Euan Fraser Proud, Pharmacist, United Kingdom; Kerry Mooney, Biomedical Scientist, United Kingdom; Daniel Hearsey Pharmacist, United Kingdom; Ololade Agbeyomi, Pharmacist, United Kingdom; Catherine Jeppesen, Consultant, United Kingdom; Kirsteen Hill, Pharmacist, United Kingdom; Dr Charles Ochero Cornelio Langoya, ID/Micro Trainee, United Kingdom; Cristina Moreno Lozano, PhD Student, United Kingdom; Robert Weir, Microbiologist, United Kingdom; Ms Emma Meadley, Biomedical Scientist, United Kingdom; Jenna Gillies, Consultant, United Kingdom; Padmaja Polubothu, Consultant, United Kingdom; Stuart Hannah, Research Fellow, United Kingdom; Brieze Read, Policy / Government / Civil Service, United Kingdom; Avneet Shahi, ID/Micro Trainee, United Kingdom; Fionna Pursey, Policy / Government / Civil Service, United Kingdom; Konstantina Tsaprouni, Microbiologist, United Kingdom; Dr Kirsty Jane McLean, Clinical Lecturer, United Kingdom; Lorraine Cullen, Pharmacist, United Kingdom; Hannah Lowe, Clinical Scientist, United Kingdom; Ms Amy Lee, Pharmacist, United Kingdom; Dr Asa Auta, Clinical Lecturer, United Kingdom; Mr Timothy Luxton, PhD Student, United Kingdom; Dr Jessica Martin, Specialist Doctor / Consultant, United Kingdom; Miss Sarah Hackney, Pharmacist, United Kingdom; Mathew Crowther, Working in Industry – Pharma, United Kingdom; Kathryn Ball, Biomedical scientist, United Kingdom; Lance Turtle, Consultant, United Kingdom; Miss Natasha Champa Niethamer, Research Assistant, United Kingdom; Dr Daire Cantillon, Research Fellow, United Kingdom; Jane Johnson, Biomedical Scientist, United Kingdom; Kim Sorley, Clinical Research Nurse, United Kingdom; Adela Alcolea-Medina, Clinical Scientist, United Kingdom; Kerry Roulston, Clinical Scientist, United Kingdom; Amelia Andrews, Epidemiologist, United Kingdom; Abdi Hasaan, Laboratory Practitioner, United Kingdom; Jasmin Islam, Microbiologist, United Kingdom; Dr Sara Hillyer, Other – Intern, United Kingdom; Ahmad Simreekheea , Pharmacist, United Kingdom; Laura Whitney, Pharmacist, United Kingdom; Ebenezer Foster-Nyarko, Research Fellow, United Kingdom; Omotayo Olaoye, Research Fellow, United Kingdom; Madeline Murphy, Specialist Doctor / Consultant, United Kingdom; Mr Divyangkumar Jaysukhbhai Butani, Student, United Kingdom; Rita Ramalhete, Student, United Kingdom; Gina Chen, Technical Officer, United Kingdom; Dr Nicolas Massie, Trainee (ID/Micro), United Kingdom; Karishma Gokani, Trainee (ID/Micro), United Kingdom; Oliver Fletcher, Trainee (ID/Micro), United Kingdom; Rohan Mehra, Trainee (ID/Micro), United Kingdom; Linda Cheyenne Vaccari, Trainee (other), United Kingdom; Preety Ramdut, Pharmacist, United Kingdom; Andrew Fox, Clinical Scientist, United Kingdom; Jake Parkes, Microbiologist, United Kingdom; Dr Narjes Chyad Alfuraiji, PhD Student, United Kingdom; Isabelle Storer, PhD Student, United Kingdom; Mr Krishna Sanjay Chellappa, PhD Student, United Kingdom; Dr Paddy McMaster, Specialist Doctor / Consultant, United Kingdom; Adam Hawker, Trainee (Other), United Kingdom; Ms Stephen Harwood, Trainee (ID/Micro), United Kingdom; Anastasia Kolyva, Microbiologist (Clinical), United Kingdom; Caroline Herin, Pharmacist, United Kingdom; Dr Bipin Adhikari, Research Fellow, United Kingdom; Robert Tilley, Consultant, United Kingdom; Katie Muddiman, Research Fellow, United Kingdom; Sarah Wyllie, Microbiologist (Clinical), United Kingdom; Margaret Skyrme, Biomedical Scientist, United Kingdom; Tamara Mitchell, Consultant, United Kingdom; Elise Bale, Student, United Kingdom; Clare Mckoen, Biomedical Scientist, United Kingdom; Wathsala Galagedara, International Training Fellow Medical Microbiology, United Kingdom; Scott Rory Hicks, ID/Micro Trainee, United Kingdom; Reela Varghese, Microbiologist (Clinical), United Kingdom; Ching-Yan Hui, Pharmacist, United Kingdom; Athanasios Nikolaou, Research Fellow, United Kingdom; Ms Lesley Durant, Specialist Nurse, United Kingdom; Dr Claire Louise Price, Research Fellow, United Kingdom; Katy Talbot, Biomedical scientist, United Kingdom; Dominic Heining, ID/Micro Trainee, United Kingdom; Mr Paul Andreianu, Specialist Doctor / Consultant, United Kingdom; Catherine Hatch, Biomedical Scientist, United Kingdom; Megan Dawson, Laboratory Practitioner, United Kingdom; Claudia Mongiano De D'Abrantes, Pharmacist, United Kingdom; Mrs Emma Griffiths, Biomedical Scientist, United Kingdom; Mrs Rajdip Anderson, Biomedical Scientist, United Kingdom;

Connor Wainwright, Pharmacist, United Kingdom; Donna Lecky , Policy / Government / Civil Service, United Kingdom; Mr Oluwamayowa Samuel Akinsuyi, Other - Graduate Assistant, United States of America; Mr Kayode Gabriel Adeyemi, Other - Teaching Assistant, United States of America; Dr Christian M. Gill, Other - Associate Director, Unites States of America; Bright Nsokolo, Specialist Doctor / Consultant, Zambia.

Memorandum of Association

- 1 The name of the company (hereinafter called "the Society") is "BRITISH SOCIETY FOR ANTIMICROBIAL CHEMOTHERAPY".
- 2 The registered office of the Society will be situate in England and Wales.
- 3 The objects for which the Society is established ("the Objects") are to facilitate the acquisition and dissemination of knowledge in the field of antimicrobial chemotherapy .
- 4 In furtherance of the Objects, but not otherwise, the Society may exercise the following powers:-
 - 4.1 to institute or assist in instituting, and provide continuing support for, any research in furtherance of the Objects;
 - 4.2 to cause to be written, published, produced and circulated, and to encourage contributions to and publication and production of, periodicals, journals, books, papers, abstracts, pamphlets, posters and other documents and films, videos, recorded tapes and communications in any medium;
 - 4.3 to provide, equip and manage libraries and sources of information in any medium and rooms for the benefit of members of the Society and others;
 - 4.4 to co-operate with persons carrying on research relating to antimicrobial chemotherapy in any part of the world;
 - 4.5 to act as a consultative body on antimicrobial chemotherapy to any Government Department, public or private institution or body of persons on matters pertaining to the Objects;
 - 4.6 to endow Chairs, Readerships, Scholarships, Fellowships and Lectureships at, and provide other support to, appropriate institutions to facilitate the conduct of study and research in furtherance of the Objects;
 - 4.7 to disseminate the useful results of research in furtherance of the Objects;
 - 4.8 to sponsor and hold meetings, symposia, conferences, lectures, classes, seminars, courses and exhibitions either alone or with others;
 - 4.9 to award scholarships, bursaries and prizes in connection with the Society's objects;
 - 4.10 to foster and promote contacts and exchange of information and ideas among persons working in the field of antimicrobial chemotherapy, medical practitioners and other health professionals and the public and to provide a forum to this end;
 - 4.11 to take such steps as may be required for the purpose of procuring contributions to the funds of the Society by way of subscriptions, donations, devises, bequests, grants, subventions or otherwise, provided that in raising funds the Society shall not undertake any taxable trading activities the profits of which are liable to tax;
 - 4.12 to take and accept any gift of money, property or other assets, whether subject to any special trust or not, for any one or more of the objects of the Society;
 - 4.13 to purchase, take on lease or in exchange, hire or otherwise acquire and hold any real or personal property or rights, and to construct, alter, improve, develop, manage and maintain any of the same as are necessary or convenient for the Objects and (subject to such consents as may be required by law) sell, let or otherwise dispose of, turn to account or charge any such real or personal property as may be thought expedient in furtherance of the Objects;
 - 4.14 to apply for, purchase or otherwise acquire and hold or use any patents, copyrights, trade marks, design rights and other intellectual property rights, licences, concessions and the like, conferring any right to use or publish any information, and to use, exercise, develop or grant licences in respect of the property, rights or information so acquired;
 - 4.15 to draw, make, accept, endorse, discount, execute and issue promissory notes, bills, cheques and other instruments and to operate bank or building society accounts in the name of the Society;
 - 4.16 to borrow or raise money for the purposes of the Society on such terms and (subject to such consents as may be required by law) on such security as may be thought fit;
 - 4.17 subject to the provisions of Clause 5 below, to employ such staff (not being members of the Council) as are necessary for the proper pursuit of the Objects and to make all reasonable and necessary provision for the payment of pensions and superannuation to or on behalf of employees, their widows or widowers and other dependants;
 - 4.18 to invest the moneys of the Society not immediately required for the Objects in or on such investments, securities or property and in such manner as may be thought fit and to dispose of or otherwise deal with any investments so made;
 - 4.19 to make any donation either in cash or assets for the furtherance of the Objects;
 - 4.20 to establish and support or aid in the establishment or support of, subscribe to or become a member of any charitable trust, association or institution having charitable purposes in any way connected with all or any of the Objects or calculated to further any of the Objects and to guarantee money for charitable purposes in any way connected with all or any of the Objects or calculated to further all or any of the Objects;
 - 4.21 to undertake and execute any charitable trusts which may lawfully be undertaken by the Society and may promote the Objects;
 - 4.22 to co-operate or associate with other charities, voluntary bodies and statutory authorities operating in furtherance

- of the Objects or similar charitable purposes and to exchange information and advice with them;
- 4.23 to acquire and undertake all or any part of the property, assets, liabilities and engagements of any persons, trusts, corporations, associations or other bodies pursuing the Objects;
- 4.24 to amalgamate with any charity operating in furtherance of the Objects or similar charitable purposes;
- 4.25 to insure and arrange insurance cover for and to indemnify employees, voluntary workers and members from and against all such risks incurred in the course of the performance of their duties in relation to the Society, provided that such persons shall not be indemnified against any wilful or individual fraud and shall be sought to be made liable for such acts;
- 4.26 to establish subsidiary companies;
- 4.27 to pay out of the funds of the Society the costs, charges and expenses of and incidental to the formation and registration of the Society;
- 4.28 to do all such other lawful things as are necessary for the achievement of the Objects or any of them.
- 5 The income and property of the Society shall be applied solely towards the promotion of the Objects and no part shall be paid or transferred, directly or indirectly, by way of dividend, bonus or otherwise by way of profit, to members of the Society and no member of Council shall be appointed to any office of the Society paid by salary or fees or receive any remuneration or other benefit in money or money's worth from the Society provided that nothing in this document shall prevent the payment in good faith by the Society:
- 5.1 of reasonable and proper remuneration to any member, officer or employee for the Society (not being a member of Council) for any services rendered to the Society;
- 5.2 of interest at a reasonable and proper rate on money lent to the Society or of reasonable and proper rent for premises demised or let to the Society by any member or employee of the Society or member of Council;
- 5.3 to any employee or member of Council or of a committee or sub-committee of the Council for reasonable and proper out-of-pocket expenses;
- 5.4 of fees, remuneration or other benefit in money or money's worth to a company of which a member of the Society or of Council may be a member holding not more than one hundredth part of the issued share capital of that company;
- 5.5 of any premium in respect of any indemnity insurance to cover the liability of the members of the Council or of any committee which by virtue of any rule of law would otherwise attach to them in respect of any negligence, default, breach of trust or breach of duty of which they may be guilty in relation to the Society: Provided that any such insurance shall not extend to any claim arising from any act or omission which the members of the Council or of any committee knew to be a breach of trust or breach of duty or which was committed by the members of the Council or of any committee in reckless disregard of whether it was a breach of trust or breach of duty or not and Provided also that any such insurance shall not extend to the costs of an unsuccessful defence to a criminal prosecution brought against the members of Council in their capacity as members of the Council.
- 6 The liability of the members is limited.
- 7 Every member of the Society undertakes to contribute such amount as may be required (not exceeding £1) to the Society's assets if it should be wound up while he is a member or within one year after he ceases to be a member, for payment of the Society's debts and liabilities contracted before he ceases to be a member, and of the costs, charges and expenses of winding up, and for the adjustment of the rights of the contributories among themselves.
- 8 If upon the winding up or dissolution of the Society there remains after satisfaction of its debts and liabilities any property, the same shall not be paid to or distributed among the members of the Society but shall be given or transferred to some other charitable institution or institutions having objects similar to the Objects, which prohibits or prohibit the distribution of its or their income and property to an extent at least as great as imposed on the Society by Clause 5 above, such institution or institutions

Articles of Association

1 DEFINITIONS AND INTERPRETATION

- 1.1 In these Articles the following words and expressions shall have the following meanings:
- “the Articles”** these Articles of Association of the Society;
- “clear days”** in relation to a period of notice means the period excluding the day when the notice is given or deemed to be given and the day for which it is given or on which it is to take effect;
- “communication”** as defined by in the Electronic Communications Act 2000 (as modified or re-enacted from time to time);
- “the Companies Act”** the Companies Act 1985 including any statutory modification or re-enactment of any of its provisions for the time being in force;
- “the Council”** the board of directors of the Society for the time being;
- “electronic communication”** as defined in the Electronic Communications Act 2000 (as modified or re-enacted from time to time);
- “the General Secretary”** the Secretary of the Society or any other person appointed to perform the duties of the secretary of the Society, including a joint, assistant or deputy secretary;
- “Member”** a member of the Society for the time being whether an Ordinary Member, Honorary Member or Retired Member;
- “the Registered Office”** the registered office of the Society;
- “the Regulations”** the regulations of the Society made by the Council pursuant to Article 78 or any other Article;
- “the Society”** the company known as “British Society for Antimicrobial Chemotherapy”;
- “the Unincorporated Society”** the unincorporated association known as “British Society for Antimicrobial Chemotherapy”;
- “United Kingdom”** Great Britain and Northern Ireland;
- “in writing”** written, printed, lithographed, photographed or partly one and partly another, or produced by other modes of representing or reproducing words in a visible form.
- 1.2 Words importing the singular number shall include the plural number, and vice versa and words importing persons shall include corporations.
- 1.3 Unless the context otherwise requires, words or expressions contained in these Articles shall bear the same meaning as in the Companies Act or any statutory modification or re-enactment of the Companies Act in force at the date of the adoption of the Articles.

2 OBJECTS

The Society is established for the objects expressed in the Memorandum of Association of the Society.

3 THE TRUSTEES AND DIRECTORS

The elected members of the Council are charity trustees within the definition of the Charities Act 1993 (as modified or re-enacted from time to time) and also directors of the Society as the persons having the general control and management of the administration of the Society.

4 MEMBERS

The first Ordinary Members shall be the subscribers to the Memorandum of Association and those other persons who are ordinary members of the Unincorporated Society at the date of incorporation of the Society. The first Honorary Members and the first Retired Members shall be respectively those who honorary members and retired members of the Unincorporated Society at the date of incorporation of the Society.

5 There shall be the following classes of Members of the Society:

- 5.1 Ordinary Members
- 5.2 Honorary Members
- 5.3 Retired Members

6 A person shall not be eligible to be elected as an Ordinary Member unless they are engaged in research or education in, or development or clinical use of, or have a demonstrable interest in the field of antimicrobial chemotherapeutic agents.

7 Ordinary Members shall be elected by the Council in accordance with the Regulations and the names of Ordinary Members elected shall be disclosed at the Annual General Meeting next following their election.

8 Honorary Members shall be elected by Ordinary and Retired Members at an Annual General Meeting of the Society in

accordance with the Regulations.

- 9** An Ordinary Member may become a Retired Member in accordance with the Regulations.
- 10** Subject to the provisions of the Articles, the Council shall by Regulations prescribe the eligibility criteria and the conditions for the acceptance for each class of Membership, the procedures for application and election to each class of Membership and the privileges of Membership.
- 11** The rights and privileges of every Member shall be personal to himself, shall not be transferable and shall cease on death.
- 12** A Register shall be kept at the Registered Office in which shall be entered the name and address of every Member.
- 13** 13.1 All Ordinary Members and Honorary Members shall be entitled to attend, speak, and vote at General Meetings of the Society.
13.2 Retired Members shall be entitled to receive notice of General Meetings and to attend and speak, but not vote, at General Meetings.

TERMINATION OF MEMBERSHIP

- 14** A Member shall cease to be a Member if:
- 14.1 by at least one month's notice in writing to the General Secretary to resign membership;
- 14.2 the Council or any committee of the Council, after due enquiry, resolves that the interests of the Society so require.
- 15** In the event of any Member ceasing to be a Member under Articles 14 or 17 their name shall be removed from the Register and they will not be entitled to describe themselves as being a Member or to any of the privileges of a Member.

FEES AND SUBSCRIPTIONS

- 16** Membership of the Society does not require payment of a fee or subscription, other than when a member elects to receive the Journal of Antimicrobial Chemotherapy (JAC) by either electronic or published formats, or any other subscription-based benefit as may be advertised from time to time. There will be separate charges for receipt of the JAC by either electronic or published formats and for the receipt of any other subscription-based benefits as may be available from time to time. The subscription or fee for receipt of the Journal or subscription-based benefits shall be notified to members each year and the level of fees and subscriptions reviewed and agreed by Council from time to time.
- 17** A member who is in arrears with the fee or subscription charged will be notified in writing, by either email or letter, that they are in arrears and will be notified of the date by which the arrears must be paid.
- 18** Failure to pay the arrears will result in the Society ceasing access to electronic copies of the JAC and cancellation of printed copies of the JAC.
- 19** In circumstances described in paragraph 18 above the Member will remain a Member of the Society but will not receive JAC.

REINSTATEMENT

- 20** Where any Member has ceased to be a Member for any reason, that person may only be reinstated as a Member if re-elected in accordance with Articles 7 or 8.

GENERAL MEETINGS

- 21** The Society shall hold a General Meeting in every calendar year as its Annual General Meeting in addition to any other General Meetings in the year. The Annual General Meeting shall be held on the date and at the time and place determined by the Council, and it shall be specified to be the Annual General Meeting in the notice calling it. Not more than fifteen months shall elapse between one Annual General Meeting and the next provided that so long as the Society holds its first Annual General Meeting within eighteen months of its incorporation it need not hold it in the year of its incorporation or in the following year.
- 22** All General Meetings, other than the Annual General Meeting, shall be called Extraordinary General Meetings.
- 23** 23.1 The President or the Council may whenever deemed appropriate call General Meetings and, on the requisition of not less than 30 Ordinary Members and Honorary Members, shall forthwith proceed to convene an Extraordinary General Meeting.
23.2 Any requisition shall express the object of the meeting proposed to be called and shall be left at the Registered Office.
23.3 Upon receipt of such requisition the General Secretary shall forthwith proceed to convene an Extraordinary General Meeting. If he does not convene one within 28 days from the date of the requisition, the requisitioners may themselves convene an Extraordinary General Meeting.

NOTICE OF GENERAL MEETINGS

- 24** An Annual General Meeting and an Extraordinary General meeting shall be called by at least twenty-one clear days' notice. A General Meeting may, however, be called by a shorter notice if it so agreed:
- 24.1 in the case of an Annual General Meeting, by all the Members entitled to attend and vote; and
- 24.2 in the case of any other meeting by a majority in number of Members having a right to attend and vote, being a majority together holding not less than 95 percent of the total voting rights at the meeting of all the Members.
- The notice shall specify the time and place of the meeting and the general nature of the business to be transacted and, in the case of an Annual General Meeting, shall specify the meeting as such.
- The notice shall be given to all the Members, the members of Council and the auditors.
- 25** The accidental omission to give notice of a meeting to, or the non-receipt of notice of a meeting by, any person entitled to receive notice shall not invalidate the proceedings at that meeting.

PROCEEDINGS AT GENERAL MEETINGS

- 26** No business shall be transacted at any General Meeting of the Society unless a quorum of Members is present at the time when the meeting proceeds to business. Thirty persons being Ordinary Members or Honorary Members entitled to vote upon the business to be transacted and being present in person or by a proxy shall be a quorum at any General Meeting.
- 27** If such a quorum is not present within half an hour from the time appointed for the meeting, the meeting, if convened on the requisition of Members, shall be dissolved and in any other case shall stand adjourned to the same day in the next week at the same time and place or to such other day not less than seven and not more than twenty eight days after the meeting and at the time and place as the Council may determine. If at such adjourned meeting a quorum is not present within half an hour from the time appointed for holding the meeting the Members present in person or by a proxy shall form a quorum (subject to being not less than twenty persons being Ordinary Members or Honorary Members and otherwise the meeting shall be dissolved).
- 28** The President, if any, or in their absence one of the other Officers present shall preside as the chairperson at Annual General Meetings and Extraordinary General Meetings, but if neither the President nor any other Officer be present within fifteen minutes after the time appointed for holding the meeting and willing to act, the members of Council present shall elect one of their number to be chairperson but if there is no member of Council present and willing to act, the Ordinary Members and Honorary Members present shall elect one of their number to be chairperson.
- 29** The chairperson of any General Meeting may, with the consent of a meeting at which a quorum is present (and shall if so directed by the meeting), adjourn the meeting from time to time and from place to place, but no business shall be transacted at any adjourned meeting other than business which might properly have been transacted at the meeting had adjournment not taken place. When a meeting is adjourned for fourteen days or more, at least seven clear days' notice shall be given specifying the time and place of the adjourned meeting and the general nature of the business to be transacted. Otherwise it shall not be necessary to give any such notice.
- 30** A resolution put to the vote of a General Meeting shall be decided on a show of hands unless before, or on the declaration of the result of, the show of hands a poll or secret ballot is duly demanded. Subject to the provisions of the Companies Act, a poll or secret ballot may be demanded:
- 30.1 by the chairperson of the meeting; or
- 30.2 by at least three Members having the right to vote at the meeting; or
- 30.3 by a Member or Members representing not less than one-tenth of the total voting rights of all the Members having the right to vote at the meeting and a demand by a person as a proxy for a Member shall be the same as a demand by the Member.
- 31** Unless a poll or secret ballot is duly demanded a declaration by the chairman that a resolution has been carried or carried unanimously, or by a particular majority, or lost, or not carried by a particular majority and an entry to that effect in the minutes of the meeting shall be conclusive evidence of the fact without proof of the number or proportion of the votes recorded in favour of or against the resolution.
- 32** The demand for a poll or a secret ballot may be withdrawn before the poll or the secret ballot is taken, but only with the consent of the chairman. The withdrawal of a demand for a poll or a secret ballot shall not invalidate the result of a show of hands declared before the demand for the poll or the secret ballot was made.
- 33** A poll or secret ballot shall be taken as the chairperson directs and he may appoint scrutineers (who need not be Members) and fix a time and place for declaring the result of the poll or the secret ballot. The result of the poll or secret ballot shall be deemed to be the resolution of the meeting at which the poll or secret ballot is demanded.
- 34** In the case of an equality of votes, whether on a show of hands or on a poll or a secret ballot the chairperson of the General Meeting shall be entitled to a casting vote in addition to any other vote he may have.
- 35** No poll or secret ballot shall be demanded on the election of a chairperson of a meeting or on a question of adjournment. A poll or secret ballot demanded on any other question shall be taken at such time and place as the chairperson directs

not being more than thirty days after the poll or secret ballot is demanded. The demand for a poll or secret ballot shall not prevent continuance of a meeting for the transaction of any business other than the question on which the poll or secret ballot is demanded. If a poll or secret ballot is demanded before the declaration of the result of a show of hands and the demand is duly withdrawn, the meeting shall continue as if the demand had not been made.

- 36** No notice need be given of a poll or secret ballot not taken immediately if the time and place at which it is to be taken are announced at the meeting at which it is demanded. In other cases, at least seven clear days' notice shall be given specifying the time and place at which the poll or secret ballot is to be taken.
- 37** A resolution in writing signed or approved by letter, email or electronic transmission by or on behalf of all the Members who would have been entitled to vote upon it if it had been proposed at a General Meeting shall be as valid and effectual as if it had been passed at a General Meeting duly convened and held. Any such resolution may consist of several documents in the like form each signed by or on behalf of one or more Members.

VOTES OF MEMBERS

- 38** On a show of hands every Ordinary Member and Honorary Member present in person shall have one vote and, on a poll, or secret ballot every Ordinary Member and Honorary Member present in person or by proxy shall have one vote. A proxy must be an Ordinary Member or Honorary Member. No other Members shall be entitled to vote.
- 39** No objection shall be raised to the qualification of any voter except at the meeting or adjourned meeting at which the vote objected to is tendered, and every vote not disallowed at the meeting shall be valid. Any objection made in due time shall be referred to the chairperson whose decision shall be final and conclusive.
- 40** The appointment of a proxy shall be in the form prescribed by the Council signed by the appointor or a duly authorised attorney.
- 41** The appointment of a proxy (and the power of attorney or other authority, if any, under which it is signed or a notarial certified copy) shall:
- 41.1 (in the case of an instrument in writing) be deposited at the Registered Office or at such other place within the United Kingdom as is specified for that purpose in the notice convening the meeting not less than forty-eight (48) hours before the time appointed for holding the meeting or adjourned meeting at which the proxy proposes to vote; or
 - 41.2 in the case of an appointment contained in an electronic communication, where an address has been specified for the purpose of receiving electronic communications,
 - 41.2.1 in the notice convening the meeting; or
 - 41.2.2 in any instrument of proxy sent out by the Society in relation to the meeting; or
 - 41.2.3 in any invitation contained in an electronic communication to appoint a proxy issued by the Society in relation to the meeting, be received at such address not less than forty-eight (48) hours before the time for holding the meeting or adjourned meeting at which the person named in the appointment proposes to vote; or
 - 41.3 in the case of a poll or secret ballot be deposited or received as aforesaid not less than twenty-four (24) hours before the time appointed or the taking of the poll or the secret ballot and in default of the deposit, delivery or receipt in a manner aforesaid the appointment of a proxy shall be treated as invalid.
The appointment of a proxy shall be treated as invalid twelve (12) months from its date of execution.
- 42** A vote given or poll or secret ballot demanded by a proxy shall be valid notwithstanding the previous determination of the authority of the person voting or demanding a poll or secret ballot or death of the appointor unless notice of the determination or death was received by the Society at the Registered Office or at such other place within the United Kingdom at which the instrument of proxy was duly deposited or, where the appointment of the proxy was contained in an electronic communication, at the address at which such appointment was duly received before the commencement of the meeting or adjourned meeting at which the vote is given or the poll or secret ballot demanded or (in the case of a poll or a secret ballot taken otherwise than on the same day as the meeting or adjourned meeting) the time appointed for taking the poll or the secret ballot.
- 43** In Articles 41 and 42 "address", in relation to electronic communications, includes any number or address used for the purposes of such communications.

POWERS OF THE COUNCIL

- 44** The business of the Society shall be managed by the Council who may exercise all such powers of the Society as are not required to be exercised by the Society in General Meeting. Any such requirement may be imposed either by the provisions of the statutes for the time being in force and affecting the Society or by the Articles, but no amendment to the

Articles shall invalidate any prior act of the Council which would have been valid if that amendment had not been made.

COMPOSITION OF THE COUNCIL

- 45** The Council shall consist of:
- 45.1 the Officers
 - 45.2 a maximum of ten Ordinary Council Members or such other maximum number (being not less than four) as may be determined by the Society in General Meeting.
 - 45.3 no more than 5 elected Members or Officers of Council shall reside permanently outside of the United Kingdom. The interests of international members of the Society will be represented by the appointment of an Officer for International Affairs
- 46** The first Officers and other members of Council shall be the subscribers to the Memorandum of Association who shall hold the offices and for the terms set out in the Regulations.

ELECTION OF ORDINARY COUNCIL MEMBERS

- 47** A person will only be eligible to be elected an Ordinary Council Member if he is an Ordinary or Honorary Member of the Society. Employees are not eligible for election to Council. Past employees are not eligible for election for a period of no less than five years after they left the employ of the Society.
- 48** The Ordinary Council Members shall be elected by the Ordinary Members by postal ballot.
- 49** The procedure for the nomination and election of Ordinary Council Members shall be defined in the Regulations.
- 50** The results of the election of Ordinary Council Members shall be declared at the Annual General Meeting immediately following their election. The election of new Ordinary Council Members as aforesaid shall take effect as from the close of the Annual General Meeting when the retiring Ordinary Council Members shall be deemed to retire.
- 51** An Ordinary Council Member shall hold office for a term of three years from the date of his election, at the end of which he shall retire, but shall be eligible for re-election for a second three-year term of office by Council. After this they shall not be eligible for re-election until they have been out of office for one year. For the purposes of this Article and Articles 60, 61 and 63 a "year" shall mean the period between the end of one Annual General Meeting and the end of the next Annual General Meeting of the Society.
- 52** The Council shall have power at any time to appoint any Ordinary Member of the Society to be a member of Council, to fill a casual vacancy in the Ordinary Council Members. Any member of Council so appointed shall hold office only until the next following Annual General Meeting, but they shall then be eligible for re-appointment or re-election to the Council.
- 53** The Society may by ordinary resolution, of which special notice shall have been given in accordance with Section 379 of the Companies Act, remove any member of Council before the expiration of their period of office notwithstanding anything in the Articles or in any agreement between the Society and such member of Council. The Society may by ordinary resolution appoint another person in place of a member of Council removed under this Article.

THE OFFICERS

- 54** The Officers of the Society shall be:
- 54.1 the President
 - 54.2 the Vice President
 - 54.3 the Treasurer
 - 54.4 the General Secretary
 - 54.5 the Officer for Data and Surveillance
 - 54.6 Officer for International Affairs
 - 54.7 the Grant Secretary
 - 54.8 the Education Secretary
 - 54.9 and the holder of not more than one other office (if any) as may be determined by the Council.
- The Council may prescribe the duties of the Officers.
- 55** No person may at any time hold more than one of the offices.
- 56** A person will only be eligible to be elected an Officer if he is an Ordinary Member of the Society.
- 57** All Officers shall be elected by the Council by secret ballot. The procedure for the nomination and election by secret ballot of such Officers shall be as defined in the Regulations.
- 58** The results of the election shall be declared at the Annual General Meeting next following the ballot. The election of

Officers as aforesaid shall take effect as from the close of the Annual General Meeting when the retiring Officers (if any) shall be deemed to retire.

- 59** The duties of the General Secretary shall include those applicable to a secretary under the Companies Act. In the absence of a General Secretary such duties shall fall to the Vice President.
- 60** All Officers (other than the Vice President and the President) shall hold office for a period of three years from their election, at the end of which they shall retire but, subject to the prior approval by the Council, be eligible for re-election for one further term of three years.
- 61** The President shall be elected one year in advance of taking up office as President and during that year shall be the Vice President of the Society. The President shall hold office for a period of three years, at the end of which they shall retire and not be eligible for re-election to that office. The immediate past-President shall hold office as Vice President of Society for two years following their retirement as President.
- 62** Upon completion of their term or terms of office, Officers shall not be eligible to stand for re-election to their previous office.
- 63** Vacancies in office shall be treated as follows:
- 63.1 In the event of the vacation of office pursuant to Article 76 or death of the President, during their third year in office, the Vice President (President-Elect) shall take up office immediately as President for the remainder of the unexpired term and shall then proceed to serve his three-year term as President.
- 63.2 In the event of the vacation of office pursuant to Article 76 or death of the President during either the first and second year in office, Article 61 shall be suspended (until the election by the Council of the President under Article 63.3 and subject to the provisions of that Article) and Article 63.3 shall be enacted.
- 63.3 On the occurrence of the event in Article 63.2 the Vice-President (Past-President) shall immediately become President until such time as the next President is elected by the Council by secret ballot in accordance with the procedure for the nomination and election of Officers as defined in the Regulations and pursuant to Article 58, following which the said Vice-President (Past President) shall serve in office as Vice President (Past President) for further two years. The President so elected by the Council shall hold office for a period of three years, at the end of which they shall retire and not be eligible for re-election to that office.
- 63.4 The Council may at any time elect a person to fill a vacancy in any Office, save for the office of President the procedure for which is as defined in Articles 63.1 to 63.3, and such person must be an Ordinary Member. Any person so elected shall hold office until the next Annual General Meeting.

CO-OPTEEES

- 64** The Council shall have the power at any time to co-opt to the Council any person who is an Ordinary Member or Honorary Member. Any person so co-opted shall hold office until the next Annual General Meeting but may then be co-opted at any time thereafter. Any person so co-opted shall be entitled to attend and speak at any meeting of the Council but not to vote on any question arising at a Council meeting.

PROCEEDINGS OF THE COUNCIL

- 65** Subject to the provisions of the Articles, the Council may regulate their proceedings as they think fit, including conducting business in person or by electronic means. The President or any three members of Council may, and on the request of the President or any three members of Council, the General Secretary shall, at any time summon a meeting of the Council by serving at least twenty-eight days' notice (or such shorter notice period as may be agreed by all members of the Council) on each member of Council at their address (electronic communication is permitted).
- 66** Questions arising at a meeting of the Council shall be decided by a majority of votes. In the case of an equality of votes, the chairperson of the meeting shall have a second or casting vote.
- 67** The quorum for the transaction of the business of the Council may be fixed by the Council and, unless fixed, shall not be less than seven members of Council, at least four of whom shall be Ordinary Council Members.
- 68** The President, or in their absence, a member of Council nominated by the President, shall chair all meetings of the Council at which they shall be present, but if at any meeting neither the President nor such nominee is willing to preside or neither is present within five minutes after the time appointed for holding the meeting, the Council present shall elect one of their number to chair the meeting.
- 69** The Council may delegate any of its powers to committees consisting of such persons as the Council may think fit. All such committees shall, in the exercise of powers so delegated, conform to any regulations imposed on them by the Council. The meetings and proceedings of all committees shall be governed by the provisions of the Articles for regulating the meetings and proceedings of the Council so far as applicable and except where these Articles or any regulations of the Council otherwise provide. All committees shall fully report their acts and proceedings to the Council as soon as is reasonably practicable.

- 70** All acts bona fide done by the Council or any of its committees, or by any person acting as a member of Council, shall, despite the later discovery that there was some defect in the appointment or continuance in office of any member of Council or of any committee or that any member of Council was disqualified, be as valid as if every such person had been duly appointed, had duly continued in office and was qualified to be a member of Council or member of the relevant committee.
- 71** The Council shall cause proper minutes to be made of the proceedings of all meetings of the Society, the Council and its committees, and all business transacted at such meetings. Any such minutes, if purporting to be signed by the chairman of the meeting or by the chairman of the next succeeding meeting, shall be sufficient evidence without any further proof of the facts stated in the minutes.
- 72** The Council may act notwithstanding any vacancy in its body, but, if and so long as its number is reduced below the number fixed by or pursuant to the Articles as the necessary quorum of members of the Council, the Council may act for the purpose of increasing the number of members of Council to that number or of summoning a General Meeting of the Society but for no other purpose.
- 73** A resolution in writing of the Council or of any of its committees signed or approved by letter or electronic communication by all the members of Council or all the members of the committee entitled to receive notice of a meeting of the Council or of its committees shall be as valid and effective as if it had been passed at a meeting of the Council or (as the case may be) its committees duly convened and held. Such a resolution may consist of several documents in the same form, each signed or approved by one or more members of Council or members of the committees of the Council, as the case may be.
- 74** All or any of the members of Council or any committee of the Council may participate in a meeting of the Council or that committee by electronic means. A person so participating shall be deemed to be present in person at the meeting and shall be entitled to vote or be counted in a quorum accordingly. Such a meeting shall be deemed to take place where the largest of the group of those participating is assembled, or, if there is no such group where the chairman of the meeting then is.

EXPENSES

- 75** Members of the Council and of committees of the Council shall be entitled to be reimbursed proper and reasonable travelling and other out-of-pocket expenses incurred in attending meetings of the Council or of such committees or General Meetings of the Society or otherwise incurred in or about the affairs of the Society.

DISQUALIFICATION OF MEMBERS OF COUNCIL

- 76** The office of a member of Council shall be vacated if they:
- 76.1 become bankrupt or makes any arrangement or composition with his creditors generally; or
 - 76.2 become incapable by reason of mental disorder, illness or injury of managing or administering his property or affairs; or
 - 76.3 resigns their office by written notice to the General Secretary; or
 - 76.4 becomes disqualified by law from acting as the trustee of a charity or as a company director; or
 - 76.5 is removed from office by a resolution of the Society duly passed pursuant to Article 53 or Section 303 of the Companies Act; or
 - 76.6 is directly or indirectly interested in any contract or proposed contract with the Society and fails to declare the nature of his interest as required by Section 317 of the Companies Act; or
 - 76.7 is absent without the permission of the Council for three consecutive meetings of the Council and the Council resolves that his office be vacated; or
 - 76.8 ceases to be a Member.

PATRONS OF THE SOCIETY

- 77** The Council may from time to time invite persons who are eminent and distinguished to accept the office of Patron of the Society. Such persons shall enjoy such privileges as the Council may confer upon them, but shall not be entitled to vote on any motion at any of the meetings of the Council, of any committees or at any General Meeting.

REGULATIONS

- 78** The Council may from time to time make such regulations as it may think fit and add to, repeal, or vary any such regulations. All regulations so made and for the time being in force shall be binding on all Members and the Council shall adopt such means as it may think fit to bring such regulations to the notice of Members. Regulations may concern the following subjects:
- 78.1 the procedure at General Meetings and meetings of the Council and its committees insofar as such procedure is not regulated by the Articles;
 - 78.2 the procedure for, and the conduct of, nominations and elections of Officers and other members of Council insofar

as not regulated by the Articles;

78.3 any other subjects which the Articles provide may be covered by Regulations;

78.4 generally all such matters as are commonly the subject matter of company rules or bye-laws provided that no regulation shall contravene any of the provisions of the Memorandum of Association of the Society, the Articles, or the Companies Act.

THE SEAL

79 The common seal of the Society shall only be used by the authority of a resolution of the Council or of a committee of the Council authorised for the purpose by the Council. Every document to which the common seal is affixed shall be signed by at least two persons appointed by the Council for such purpose.

ACCOUNTS

80 The Council shall cause proper accounting records to be kept in accordance with Section 221 of the Companies Act or any succeeding Act

81 The accounting records of the Society shall be kept at the Registered Office, or subject to Section 222 of the Companies Act or succeeding section or Act, at such other place or places as the Council shall think fit, and shall always be open to inspection by the members of Council.

82 The Council may by Regulations impose reasonable restrictions as to the time and manner at and in which the accounting records of the Company may be inspected by the Members and subject to these restrictions the accounting records shall be open to inspection by the Members during usual business hours.

AUDIT

83 Any appointment of Auditors required by the Companies Act and the duties of such auditors (if required) shall be regulated in accordance with Sections 236, 237, 241 and 384 of the Companies Act or succeeding sections or Acts, the members of the Council being treated as the directors mentioned in those sections.

BANK ACCOUNT

84 Any bank account in which any part of the assets of the Society is deposited shall be operated by the Council and shall indicate the name of the Society. All cheques, negotiable instruments, and orders for the payment of money from such account shall be signed in such manner as the Council shall from time to time determine.

INVESTMENTS

85 The Council shall have the power to employ as a professional investment manager for the Society any person who is entitled to carry [out an investment business under the provisions of the Financial Services Act 1986] OR [on a regulated activity under the provisions of the Financial

Services and Markets Act 2000] (or any statutory modification or re-enactment thereof) and to delegate to any such manager ("the Manager") the exercise of all or any of the power of investments on such terms and at such reasonable remuneration as the Council may see fit but always subject to the following:-

85.1 Delegated powers shall be exercisable only within the clear policy guidelines drawn up in advance by the Council;

85.2 Every transaction carried out by the Manager under delegated powers shall be reported to the next meeting of the Council or any committee designated by the Council for such purpose;

85.3 The Council shall be entitled at any time and without notice to review, revoke or alter the delegation or the terms thereof;

85.4 The Council will be bound to review the arrangements for delegation at least once in every 12 months;

85.5 The Manager shall keep the Council informed on a regular basis of the performance of the investment portfolio managed by the Manager.

86 The Council may:

86.1 make such arrangements as they think fit for any investments of the Society or income from those investments to be held by a corporate body which is incorporated in England or Wales (or which has established a branch or a place of business in England and Wales) as the Council's nominee; and

86.2 pay reasonable and proper remuneration to any corporate body acting as the Council's nominee in pursuance of this Article.

INDEMNITY

- 87** Subject to the provisions of the Companies Act, every member of Council, or other officer or auditor of the Society, shall be indemnified out of the assets of the Society against any liability incurred by them in that capacity in defending any proceedings, whether civil or criminal, in which judgment is given in their favour or in which they are acquitted or in connection with any application in which relief is granted to them by the Court from liability for negligence, default, breach of duty or breach of trust in relation to the affairs of the Society.

DISSOLUTION

- 88** Clause 8 of the Memorandum of Association of the Society relating to the winding up and dissolution of the Society shall have effect as if its provisions were repeated in the Articles.

NOTICES

- 89** Any notice to be given to or by any person pursuant to the Articles (other than a notice calling a meeting of the Council or of any of its committees) shall be in writing or shall be given using electronic communications to an address for the time being notified for that purpose to the person giving the notice.
- 90** The Society may give any notice to a Member either personally or by sending it by post in a prepaid envelope addressed to the Member at his registered address or by leaving it at that address or by giving it using electronic communications to an address for the time being notified to the Society by the member.
- 91** Proof that an envelope containing a notice was properly addressed, prepaid, and posted shall be conclusive evidence that the notice was given. Proof that a notice contained in an electronic communication was sent in accordance with guidance issued by the Institute of Chartered Secretaries and Administrators shall be conclusive evidence that the notice was given. A notice shall be deemed to be given at the expiration of 72 hours (120 hours if sent by airmail) after the envelope containing it was posted or, in the case of a notice contained in an electronic communication, at the expiration of 48 hours after the time it was sent.
- 92** In Articles 89 and 90 "address" in relation to electronic communications includes any number or address used for the purpose of such communications.

